<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" article-type="research-article">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">WASJ</journal-id>
<journal-title-group>
<journal-title>World Academy of Sciences Journal</journal-title>
</journal-title-group>
<issn pub-type="ppub">2632-2900</issn>
<issn pub-type="epub">2632-2919</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">WASJ-6-6-00268</article-id>
<article-id pub-id-type="doi">10.3892/wasj.2024.268</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Identification of common biomarkers affecting patient survival in cancers</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Singh</surname><given-names>Pratik</given-names></name>
<xref rid="af1-WASJ-6-6-00268" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Patel</surname><given-names>Mansi</given-names></name>
<xref rid="af2-WASJ-6-6-00268" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bhowmik</surname><given-names>Doulat</given-names></name>
<xref rid="af1-WASJ-6-6-00268" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kumari</surname><given-names>Neha</given-names></name>
<xref rid="af1-WASJ-6-6-00268" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Prajapati</surname><given-names>Suresh Kumar</given-names></name>
<xref rid="af2-WASJ-6-6-00268" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Gupta</surname><given-names>Reeshu</given-names></name>
<xref rid="af1-WASJ-6-6-00268" ref-type="aff">1</xref>
<xref rid="af2-WASJ-6-6-00268" ref-type="aff">2</xref>
<xref rid="c1-WASJ-6-6-00268" ref-type="corresp"/>
</contrib>
</contrib-group>
<aff id="af1-WASJ-6-6-00268"><label>1</label>Parul Institute of Applied Sciences, Parul University, Vadodara, Gujarat 391760, India</aff>
<aff id="af2-WASJ-6-6-00268"><label>2</label>Centre of Research for Development, Parul University, Vadodara, Gujarat 391760, India</aff>
<author-notes>
<corresp id="c1-WASJ-6-6-00268"><italic>Correspondence to:</italic> Dr Reeshu Gupta, Centre of Research for Development, Parul University, Post Limda, Waghodia, Vadodara, Gujarat 391760, India <email>reeshu.gupta25198@paruluniversity.ac.in WDQ714619@163.com </email></corresp>
</author-notes>
<pub-date pub-type="collection">
<season>Nov-Dec</season>
<year>2024</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>07</month>
<year>2024</year></pub-date>
<volume>6</volume>
<issue>6</issue>
<elocation-id>53</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>04</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>07</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2024 Singh et al.</copyright-statement>
<copyright-year>2024</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license>
</permissions>
<abstract>
<p>The identification of genetic biomarkers that play a crucial role in cancer survival is challenging, but requires attention. The present study aimed to identify common biomarkers that affect the survival of patients with cancer. For this purpose, The Cancer Genome Atlas datasets of liver, lung, cervical and pancreatic cancers were used to identify differentially expressed genes (DEGs) that have an impact on cancer survival. The STRING database and ComplexHeatmap package were used to develop a protein-protein interaction network and heatmaps of the DEGs, respectively. The inhibitors of DEGs were identified using CMap software. Molecular docking and molecular dynamics simulations were performed using PyRx and NAMD software. Of note, two common genes [human NDC80 kinetochore complex component (<italic>NDC80</italic>) and human disks large-associated protein 5] in liver and lung cancers and five common genes [human minichromosome maintenance complex component (<italic>MCM)2</italic>, origin recognition complex subunit 1, cell division cycle 45, <italic>MCM3</italic> and human DNA topoisomerase II alpha] in cervical and liver cancers were found to significantly affect overall survival. Several inhibitors of these seven common genes were identified and it was found that cytochalasin (NDC80 inhibitor) demonstrated the highest binding affinity. The results of molecular dynamics suggested that cytochalasin B can be used as a therapeutic drug in cancers with a high expression of NDC80. In addition, the present study identified unique biomarkers present in specific types of cancer and these data were validated using the c-BioPortal database. The c-BioPortal data analysis demonstrated that the expression of the cytochrome P450 family 2 subfamily C member 9 and acyl-CoA dehydrogenase short chain genes, together with the American Joint Committee on Cancer Pathological Staging, can be used as prognostic markers of liver cancer recurrence (AUC value=0.71). No such data were obtained for other cancers. On the whole the present study highlights that the selection of DEGs as potential treatment targets should be based on their effects on cancer survival along with tumor stages.</p>
</abstract>
<kwd-group>
<kwd>cancer</kwd>
<kwd>biomarkers</kwd>
<kwd>survival</kwd>
<kwd>cytochalasin B</kwd>
</kwd-group>
<funding-group>
<funding-statement><bold>Funding:</bold> Intramural funding was received from Parul University for the present study (grant no. CR4D/IMSL/084).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Worldwide, cancer is the primary cause of mortality and a key obstacle to extending life expectancy. According to estimates from the World Health Organization (WHO) in 2019, cancer was the first or second major cause of mortality prior to the age of 70 years in 112 of 183 countries (<xref rid="b1-WASJ-6-6-00268" ref-type="bibr">1</xref>). Worldwide, an estimated 19.3 million new cancer cases and almost 10.0 million cancer-related deaths occurred in 2020. The global cancer burden is expected to be 28.4 million cases by the year 2040, a 47% increase from 2020, with a larger increase in transitioning (64 to 95%) vs. transitioned (32 to 56%) countries. Some types of cancer are very common, such as lung, cervical, liver and pancreatic cancer (<xref rid="b2-WASJ-6-6-00268" ref-type="bibr">2</xref>). According to GLOBOCAN, lung cancer was the second most frequently diagnosed type of cancer and the leading cause of cancer-related mortality in 2020, accounting for almost one in every ten (11.4%) diagnosed cases of cancer and one in every five (18.0%) related deaths, with an anticipated 2.2 million new cancer cases and 1.8 million deaths (<xref rid="b2-WASJ-6-6-00268" ref-type="bibr">2</xref>). Cervical cancer is the fourth most commonly diagnosed disease and the fourth most common cause of cancer-related death among females, with 604,000 new cases and 342,000 related deaths globally (<xref rid="b2-WASJ-6-6-00268" ref-type="bibr">2</xref>). In 2020, primary liver cancer was the sixth most commonly diagnosed type of cancer and the third major cause of cancer-related mortality worldwide, with ~906,000 new cases and 830,000 fatalities. Pancreatic cancer is the seventh most common cause of cancer-related mortality, accounting for almost as many deaths (466,000) as diagnoses (496,000), owing to its poor prognosis (<xref rid="b2-WASJ-6-6-00268" ref-type="bibr">2</xref>). The pathological type and clinical stage of cancers are not the only factors used to identify the overall survival (OS) and recurrence-free survival of patients with cancer. The expression and pathways regulated by tumor genes also play a crucial role in the survival of patients with cancer (<xref rid="b3-WASJ-6-6-00268" ref-type="bibr">3</xref>). Identifying cancer-specific genes or biomarkers involved in cancer development and progression helps to understand cancer pathophysiology and identify therapeutic targets (<xref rid="b4-WASJ-6-6-00268" ref-type="bibr">4</xref>). These biomarkers can be used to predict the risk, occurrence of cancer and patient outcomes (<xref rid="b5-WASJ-6-6-00268" ref-type="bibr">5</xref>). Previous studies have suggested the significance of abnormally expressed genes in early diagnosis, prognosis, disease monitoring and response to therapy in liver, lung, pancreatic and cervical cancers (<xref rid="b6-WASJ-6-6-00268 b7-WASJ-6-6-00268 b8-WASJ-6-6-00268 b9-WASJ-6-6-00268" ref-type="bibr">6-9</xref>). Therefore, research on survival-associated biomarkers may be beneficial for the treatment of these types of cancer, which may ultimately improve the OS rate of patients with cancer.</p>
<p>Currently, a large amount of functional genomic data have been generated owing to the development of high-throughput sequencing technology, which makes it possible to identify survival-associated cancer biomarkers by analyzing differentially expressed genes (DEGs) (<xref rid="b10-WASJ-6-6-00268" ref-type="bibr">10</xref>). The common issue with biomarker identification using high-throughput sequencing technologies lies in their selection and validation processes owing to the generation of large amounts of data (<xref rid="b11-WASJ-6-6-00268" ref-type="bibr">11</xref>). Other issues include a limited sample size, variations in sampling and experimental processes and high costs (<xref rid="b11-WASJ-6-6-00268" ref-type="bibr">11</xref>). To date, a number of gene expression profiling studies have been carried out in liver, lung, pancreatic and cervical cancers to identify potential biomarkers related to diagnosis, prognosis, survival, development and response to therapy (<xref rid="b12-WASJ-6-6-00268 b13-WASJ-6-6-00268 b14-WASJ-6-6-00268 b15-WASJ-6-6-00268" ref-type="bibr">12-15</xref>). For instance, Sun <italic>et al</italic> (<xref rid="b16-WASJ-6-6-00268" ref-type="bibr">16</xref>) investigated the role of exosomal copine III in colorectal cancer diagnosis and prognosis. Similarly, based on DEGs, a prognostic survival model was constructed for pancreatic cancer (<xref rid="b9-WASJ-6-6-00268" ref-type="bibr">9</xref>). To date, these biomarkers have not been used in clinical settings. In recent years, bioinformatics has been widely used for the functional analysis of genomic and proteomic data of tumors for cancer management. Advancements in bioinformation technology, the establishment of multiple public databases, and the use of analytical methodologies have resulted in the development of sophisticated tools for analyzing and identifying DEGs (<xref rid="b17-WASJ-6-6-00268" ref-type="bibr">17</xref>).</p>
<p>The aim of the present study was to identify common biomarkers associated with the survival of patients with liver, lung, cervical and pancreatic cancers. The present study identified seven common biomarkers that affect survival in four types of cancers. These biomarkers can be further used for the therapeutic targeting of cancers.</p>
</sec>
<sec sec-type="Materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Study design</title>
<p>In the present study, an <italic>in silico</italic> analysis using RNA-Seq data from The Cancer Genome Atlas (TCGA) was performed (<xref rid="b9-WASJ-6-6-00268" ref-type="bibr">9</xref>) to identify potential biomarkers and/or therapeutic targets for four types of cancer: Lung, cervical, liver and pancreatic cancer. TCGA is a database containing a large number of molecularly characterized datasets of &gt;20,000 tumors and matched normal samples, along with matching clinical information, such as drug exposure and survival rates (<xref rid="b18-WASJ-6-6-00268" ref-type="bibr">18</xref>). These genes were filtered out to identify common and unique genes for the different cancer types used in the present study. Genes that had a significant impact on the survival of patients with cancer were screened and then validated using the cBioPortal database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link>). The expression of genes common to at least two types of cancers was also evaluated in serum samples from patients with oral cancer. The identification of these common genes will help to identify the risk of cancer progression or therapeutic intervention in general. Cancer-associated unique biomarkers were also identified that can be used for the prognosis, diagnosis, or therapeutic management of the cancers studied in the present study.</p>
</sec>
<sec>
<title>Data resources</title>
<p>All available RNA-sequencing data from TCGA were retrieved using TCGAbiolinks (<xref rid="b19-WASJ-6-6-00268" ref-type="bibr">19</xref>). Briefly, gene count data from the available pre-processed data types were selected for four different types of cancer: i) Lung squamous cell carcinoma (TCGA-LUSC: 504 patients; age range, 41-84 years; disease stage, I, II, III and IV; normal samples, 51); ii) cervical squamous cell carcinoma and endocervical adenocarcinoma (TCGA-CESC: 307 patients; age range, 20-88 years; disease stage, I, II, III and IV; normal samples, 3); iii) liver hepatocellular carcinoma (TCGA-LIHC: 377 patients; age range, 16-90 years; disease stage, I, II and III; normal samples: 50); and iv) pancreatic adenocarcinoma (TCGA-PAAD: 185 patients; age range, 40-88 years; disease stage, I, II, III and IV; normal samples, 4).</p>
</sec>
<sec>
<title>Ethics approval</title>
<p>A total of 10 patients with oral cancer referred by the Parul Sevashram Hospital (Vadodara, India) were enrolled in the present study in 2023 according to the following inclusion and exclusion criteria. Inclusion criteria: Patients with biopsy proven oral cancer and who provided consent for the study were included. Exclusion criteria: i) Patients with other types of cancer; ii) patients who had undergone prior chemotherapy treatment and had known additional malignancies that progressed or required active treatment over the past 2 years; iii) patients having salivary gland disease; iv) those who did not provide consent. The blood samples (3 ml) were collected before commencing therapy and serum (~1 ml) was extracted. In addition, 5 healthy volunteers were included as the control group. All samples were collected in between February, 2023 to October, 2023. The present study was approved by the Ethics Committee of Parul University (PUIECHR/PIMSR/00/081734/5307). All methods were performed according to the relevant guidelines and regulations provided by the ethics committee of Parul University.</p>
</sec>
<sec>
<title>Differential expression analysis</title>
<p>To identify DEGs, the ‘DESeq2’ package was employed. To detect statistically significant genes, the package leverages the negative binomial distribution algorithm using the ‘DESeq’ function (<xref rid="b20-WASJ-6-6-00268" ref-type="bibr">20</xref>). Genes with counts of &lt;100 were filtered out. Genes with an absolute log2 fold change (LFC) &gt;1 and &lt;1 were considered upregulated and downregulated, respectively. Genes with a false discovery rate (FDR)-adjusted P-value of &lt;0.001 were considered statistically significant.</p>
</sec>
<sec>
<title>Interaction network construction</title>
<p>The protein-protein interaction (PPI) network of DEGs was constructed using the STRING database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://string-db.org">http://string-db.org</ext-link>) (<xref rid="b21-WASJ-6-6-00268" ref-type="bibr">21</xref>). Furthermore, the list of genes was uploaded to Cytoscape software to visualize the PPI network and analyze the structural properties of the constructed network. The high confidence (value=0.7) was used to analyze the degree of connectivity in the networks in Cytoscape software (version 3.9.1). The top genes were screened based on their high degree values.</p>
</sec>
<sec>
<title>Heatmaps construction and survival analysis</title>
<p>The selected hub genes were used to construct a heatmap for the common genes present in various types of cancer using the ComplexHeatmap package (<xref rid="b22-WASJ-6-6-00268" ref-type="bibr">22</xref>). OS analysis of TCGA data was performed using the gene expression profiling interactive analysis (GEPIA) online tool (<xref rid="b23-WASJ-6-6-00268" ref-type="bibr">23</xref>). To date, GEPIA has &gt;400 citations (<xref rid="b24-WASJ-6-6-00268" ref-type="bibr">24</xref>). GEPIA performs a survival analysis based on gene expression levels. GEPIA uses the log-rank test, often termed the Mantel-Cox test, for hypothesis evaluation. The Cox proportional hazard ratio and 95% confidence interval were also included in the survival plot. The log-rank test has optimum power under the assumption of proportional hazard rates. However, this assumption is often violated, particularly when two survival curves cross each other. In figs. 3-6, late crossing of survival curve can be seen. The authors were not able to restrict the time range in GEPIA to remove the late-stage crossover. Therefore, this may be the limitation of the present study. The cut-off criteria for log2 fold change (Log2FC) and log-rank p were set to ≥1 and &lt;0.05, respectively.</p>
</sec>
<sec>
<title>Gene Ontology (GO) and pathway analysis</title>
<p>Functional enrichment analyses were performed using the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt), which includes GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses (<xref rid="b25-WASJ-6-6-00268" ref-type="bibr">25</xref>). This analysis was performed to determine the involvement of the DEGs in various pathways and their functions.</p>
</sec>
<sec>
<title>Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)</title>
<p>The lung is the primary site of oral metastatic tumors, with no proven treatment (<xref rid="b26-WASJ-6-6-00268" ref-type="bibr">26</xref>). A recent study also supported the risk of developing lung metastasis in oral cancer (<xref rid="b27-WASJ-6-6-00268" ref-type="bibr">27</xref>). It has also been shown that liver cancer can metastasize to oral cancer (<xref rid="b28-WASJ-6-6-00268 b29-WASJ-6-6-00268 b30-WASJ-6-6-00268" ref-type="bibr">28-30</xref>). Therefore, the present study included patients with oral cancer to identify more effective and targeted treatments that can enhance the survival of patients with cancers that are capable of metastasizing to oral tissues. RNA extraction from the serum samples of 10 patients with oral cancer was performed using QIAzol reagent (cat. no. 79306, Qiagen Inc.), as previously described (<xref rid="b31-WASJ-6-6-00268" ref-type="bibr">31</xref>). Complementary DNA (cDNA) was synthesized from 500 ng RNA using a G-Biosciences cDNA synthesis kit (cat. no. 786-5020). The resulting cDNA was used for qPCR (Rotor-Gene Q, Qiagen, Inc.). qPCR was performed in triplicate with 2X SYBR-Green qPCR Master Mix from G-Biosciences (cat. no. 786-5062) under the following conditions: 95˚C for 3 min, followed by 40 cycles at 95˚C for 15 sec and 60˚C for 60 sec. The relative expression levels of the target gene mRNAs were calculated using the comparative Cq method (relative expression=2<sup>-IICq</sup>), using β-actin as an internal control (<xref rid="b32-WASJ-6-6-00268" ref-type="bibr">32</xref>). The primer sequences used were as follows: Human NDC80 kinetochore complex component (<italic>NDC80</italic>) forward, 5'-CCTCTCCATGCAGGAGTTAAGA-3' and reverse, GGTCTCGGGTCCTTGATTTTCT; human minichromosome maintenance complex component (<italic>MCM)3</italic> forward, TGGCCTCCATTGATGCTACC and reverse, GGACGACTTTGGGACGAACT; human disks large-associated protein 5 (<italic>DLGAP5</italic>) forward, AAGTGGGTCGTTATAGACCTGA and reverse, TGCTCGAACATCACTCTCGTTAT; human DNA topoisomerase II alpha (<italic>TOP2A</italic>) forward, CATTGAAGACGCTTCGTTATGG and reverse, CAGAAGAGAGGGCCAGTTGTG; human β-actin forward, GGACTTCGAGCAAGAGATGG and reverse, AGCACTGTGTTGGCGTACAG.</p>
</sec>
<sec>
<title>Molecular docking</title>
<p>Small compounds or inhibitors were selected from the connectivity map (CMap) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clue.io/about">https://clue.io/about</ext-link>). It is an online database containing information on the relationship between small-molecule compounds and various genes (<xref rid="b33-WASJ-6-6-00268" ref-type="bibr">33</xref>). Briefly, the names of DEGs were uploaded into the CMap database using its query module. The connectivity score defined the correlation between DEGs and small-molecule compounds. Negative scores indicate the therapeutic potential of a drug molecule. Therefore, the maximum negative scores were selected to predict the inhibitors of specific gene types. The structure of cytochalasin B (<italic>NDC80</italic> inhibitor) was obtained from PubChem with its compound identifier (compound identification no. 5311281). No inhibitor was found for cell division cycle 45 (<italic>CDC45</italic>), <italic>MCM</italic> and origin recognition complex subunit 1 (<italic>ORC1</italic>). Molecular docking was performed between the drug and <italic>NDC80</italic> (Protein Data Bank ID: 2IGP) using PyRx, a virtual screening tool (<xref rid="b34-WASJ-6-6-00268" ref-type="bibr">34</xref>).</p>
</sec>
<sec>
<title>Molecular dynamics (MD) simulations</title>
<p>A simulation was performed between cytochalasin B (the drug with the highest binding affinity) and <italic>NDC80</italic> using the NAMD3 system by applying a CHARMM force-field (<xref rid="b35-WASJ-6-6-00268" ref-type="bibr">35</xref>). The system build-in commands of NAMD3 were used to calculate the root mean square deviation (RMSD), root mean square fluctuation (RMSF) and radius of gyration (Rg), which were plotted using the Bio3D v2.3-0 package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://thegrantlab.org/bio">http://thegrantlab.org/bio</ext-link>). The simulation was conducted for 50 nsec. The binding free energy (ΔG) of the drug-protein complex was calculated using the NAMD energy plugin (<xref rid="b35-WASJ-6-6-00268" ref-type="bibr">35</xref>).</p>
</sec>
<sec>
<title>c-BioPortal analysis</title>
<p>To observe the effects of the expression of common and unique genes on cancer survival, RNA-seq data were downloaded from cBioPortal (TCGA, PanCancer Atlas) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cbioportal.org/datasets">https://www.cbioportal.org/datasets</ext-link>) (<xref rid="b36-WASJ-6-6-00268" ref-type="bibr">36</xref>). Samples that held data for the following parameters were selected: RNA-seq data of cancers, American Joint Committee on Cancer (AJCC) pathological staging and survival data. AJCC staging is based on the evaluation of the T (tumor), N (nodes) and M (metastasis) components of the primary cancer and the assignment of a stage grouping. Samples were divided into high- and low-risk groups based on the cut-off value of gene expression, which was determined using the median ± 3 standard error of the mean (SEM).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Common and unique DEGs were validated using available data from the cBioPortal database (<xref rid="b36-WASJ-6-6-00268" ref-type="bibr">36</xref>). Gene expression values were classified as low or high based on the cut-off values. The cut-off value was obtained using the following formula: Median ± 3SEM. The anticipated rate of distant relapse was calculated using the Breslow-type estimator of the survival function (OriginLab version 2019). The receiver operating characteristic (ROC) curves and all statistical computations were performed using OriginPro version 2019. OriginPro offers advanced statistical analysis tools and apps [Origin: Data Analysis and Graphing Software (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://originlab.com">originlab.com</ext-link>)]. These ROC curves are based on the classification model at all classification thresholds and include two parameters: True positive rate (sensitivity) and false positive rate (1-specificity). The results of RT-qPCR were analyzed using the Students t-test (unpaired). A value of P&lt;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="Results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Identification of common biomarkers in four different solid cancers</title>
<p>To explore potential biomarkers of the four different tumors, mRNA sequencing (RNA-seq) analysis was performed to identify the DEGs between the tumor and normal tissues. An integrative analysis of the RNA-seq database of TCGA-LUSC (lung), TCGA-CESC (cervical), TCGA-LIHC (liver) and TCGA-PAAD (pancreatic) cancers was performed using the TCGAbiolinks package. After processing the data, a total of 16,365, 24,777, 24,893 and 25,253 genes were differentially expressed in lung, cervical, liver and pancreatic cancer, respectively, when compared to normal tissues. These DEGs were further filtered using the criteria of log fold change ≥1 and FDR &lt;0.001. A total of 5,809 (35.49%) (upregulated, 3,156; downregulated, 2,653) genes in lung cancer, 3,043 (12.28%) (upregulated, 1,942; downregulated, 1,101) genes in cervical cancer, 6,003 (24.11%) (upregulated, 3,937; downregulated, 2,066) genes in liver cancer and 41 (0.16%) (upregulated, 32; downregulated, 9) genes in pancreatic cancer exhibited altered transcript levels when compared with normal tissues. The DEGs were then compared to identify common genes present in all four types of cancer. A total of 490 common genes (393 upregulated and 97 downregulated) were found in lung, cervical and liver cancers (<xref rid="SD3-WASJ-6-6-00268" ref-type="supplementary-material">Table SI</xref>). However, no genes were found to be common among the four cancer types. Common genes were used to establish a network to identify closely related genes. These networks were analyzed and 229 genes were extracted based on a high confidence score (<xref rid="f1-WASJ-6-6-00268" ref-type="fig">Fig. 1</xref>). The top 70 genes were selected for further analysis based on their degree and closeness values (<xref rid="SD4-WASJ-6-6-00268" ref-type="supplementary-material">Table SII</xref>). Heatmap analysis revealed the upregulation of the top 70 genes in lung (<xref rid="f2-WASJ-6-6-00268" ref-type="fig">Fig. 2A</xref>), cervical (<xref rid="f2-WASJ-6-6-00268" ref-type="fig">Fig. 2B</xref>) and liver cancer (<xref rid="f2-WASJ-6-6-00268" ref-type="fig">Fig. 2C</xref>).</p>
</sec>
<sec>
<title>Survival curves of the top 70 common genes</title>
<p>The survival plot demonstrated that only six genes (8.57%) in lung cancer, nine genes (12.85%) in cervical cancer, and 41 genes (58.57%) in liver cancer significantly affected the survival of patients with cancer (<xref rid="tI-WASJ-6-6-00268" ref-type="table">Table I</xref>). These results suggested that, irrespective of the significant upregulation of the remaining DEGs in the cancers examined, they play no significant role in the survival of these patients with cancer.</p>
</sec>
<sec>
<title>RT-qPCR analysis of common genes present in at least two types of tumors</title>
<p>The present study then attempted to identify DEGs that were present in at least two types of tumors and had a significant impact (P&lt;0.05) on OS. Based on these criteria, only two genes (<italic>DLGAP5</italic> and <italic>NDC80</italic>) in lung and liver cancers, and five genes (<italic>MCM2</italic>, <italic>MCM3</italic>, <italic>ORC1</italic>, <italic>CDC45</italic> and <italic>TOP2A</italic>) in cervical and liver cancers were identified. It was also observed that the upregulation of these genes decreased the survival of patients with liver cancer (<xref rid="f3-WASJ-6-6-00268" ref-type="fig">Figs. 3A</xref> and <xref rid="f4-WASJ-6-6-00268" ref-type="fig">4A</xref>). However, the opposite results were obtained for lung (<xref rid="f3-WASJ-6-6-00268" ref-type="fig">Fig. 3B</xref>) and cervical cancers (<xref rid="f4-WASJ-6-6-00268" ref-type="fig">Fig. 4B</xref>). High levels of these DEGs are closely associated with longer OS in lung and cervical cancers, which may be attributed to their different intracellular locations (<xref rid="b37-WASJ-6-6-00268" ref-type="bibr">37</xref>). Subsequently, the significant impact of these seven genes on disease-free survival (DFS) was only observed in liver cancer (<xref rid="f5-WASJ-6-6-00268" ref-type="fig">Figs. 5A</xref> and <xref rid="f6-WASJ-6-6-00268" ref-type="fig">6A</xref>). None of the genes significantly affected the DFS of lung (<xref rid="f5-WASJ-6-6-00268" ref-type="fig">Fig. 5B</xref>) and cervical cancers (<xref rid="f6-WASJ-6-6-00268" ref-type="fig">Fig. 6B</xref>), suggesting that these genes significantly affect the DFS of only patients with liver cancer. The log-rank test has optimum power under the assumption of proportional hazard rates. However, this assumption is often violated, particularly when two survival curves cross each other. In figs. 3-6, late crossing of survival curve can be seen. The authors were not able to restrict the time range in GEPIA to remove the late-stage crossover. Therefore, this may be the limitation of the present study. Notably, it has been proposed that when each sample size is ≥100, all the tests (Kolmogorov-Smirnov statistic, Cramér-von Mises test, Maximum of the WKM tests, and Renyi test) demonstrate powers &gt;98% regardless of the censoring rate (<xref rid="b38-WASJ-6-6-00268" ref-type="bibr">38</xref>). In all the figures (<xref rid="f3-WASJ-6-6-00268" ref-type="fig">Fig. 3</xref>, <xref rid="f4-WASJ-6-6-00268" ref-type="fig">Fig. 4</xref>, <xref rid="f5-WASJ-6-6-00268" ref-type="fig">Fig. 5</xref> and <xref rid="f6-WASJ-6-6-00268" ref-type="fig">Fig. 6</xref>), the sample size is &gt;150 and thus it should not affect the statistical analysis.</p>
<p>To increase the broad spectrum of the study, after analyzing the data on four cancers, the authors wish to evaluate the expression of common genes in other types of cancer that are relevant to the studied cancers (lung, liver, cervical and pancreatic cancer). Therefore, oral cancer samples were added to increase the broad spectrum of the study and the expression levels of all genes in serum samples from patients with oral cancer were assessed. As shown in <xref rid="f7-WASJ-6-6-00268" ref-type="fig">Fig. 7A-C</xref>, in the oral cancer samples, the expression of <italic>DLGAP5</italic> (1.53±0.22; no significant difference; <xref rid="f7-WASJ-6-6-00268" ref-type="fig">Fig. 7A</xref>), <italic>MCM3</italic> (3.56±0.42; P&lt;0.05; <xref rid="f7-WASJ-6-6-00268" ref-type="fig">Fig. 7B</xref>) and <italic>NDC80</italic> (5.01±0.35; P&lt;0.05; <xref rid="f7-WASJ-6-6-00268" ref-type="fig">Fig. 7C</xref>) was markedly higher compared with the control (healthy donor) samples. However, the expression of <italic>TOP2A</italic> (<xref rid="f7-WASJ-6-6-00268" ref-type="fig">Fig. 7D</xref>) was not markedly altered in the samples from patients with oral cancer (0.96±0.12), when compared with the healthy samples. The expression of other genes was not measurable in the serum samples of both the patients and normal samples.</p>
</sec>
<sec>
<title>GO functional and pathway enrichment analysis</title>
<p>GO functional and KEGG pathway enrichment analyses were performed to identify the potential target genes. The enriched GO functions for the target genes are presented in <xref rid="SD5-WASJ-6-6-00268" ref-type="supplementary-material">Table SIII</xref>, including the microtubule cytoskeleton organization, mitotic cell cycle, DNA metabolic process, microtubule-based process, cell cycle, regulation of mitotic cell cycle, cell cycle process, negative regulation of cell cycle, negative regulation of mitotic cell cycle, regulation of cell cycle in the biological process category; cytoskeletal part, microtubule cytoskeleton, chromosome, chromosomal part, microtubule organizing center, nuclear chromosome, nuclear chromosome part, chromosomal region, condensed chromosome, condensed nuclear chromosome in the cellular component category; and adenosine tri-phosphate binding, microtubule binding, drug binding, tubulin binding, purine nucleotide binding, adenyl nucleotide binding, ribonucleotide binding, purine ribonucleotide binding, adenyl ribonucleotide binding, purine ribonucleoside triphosphate binding in the molecular function category. The enriched KEGG pathways for the target genes included DNA replication, progesterone-mediated oocyte maturation, cell cycle, oocyte meiosis, cellular senescence, human T-cell leukemia virus 1 infection and the p53 signaling pathway (<xref rid="SD5-WASJ-6-6-00268" ref-type="supplementary-material">Tables SIII</xref> and <xref rid="SD6-WASJ-6-6-00268" ref-type="supplementary-material">SIV</xref>).</p>
</sec>
<sec>
<title>Validation of selected common genes in the cBioPortal database</title>
<p>The seven common genes identified by TCGA data analysis were validated using c-BioPortal data for the specific cancer type. Patients were divided into high- and low-risk groups based on the cut-off value (median ± SEM) of gene expression and on the basis of their impact on overall survival. First, the data for two common genes (<italic>NDC80</italic> and <italic>DLGAP5</italic>) in lung and liver cancer were validated. It was observed that out of the 133 patients with lung cancer, <italic>NDC80</italic> was increased in only 40 patients (low-risk) (30.07%) and decreased in only 32 patients (24.06%) (high-risk). For lung cancer, the data of <italic>DLGAP5</italic> were not available in the c-BioPortal database. Out of the 371 patients with liver cancer, a high expression of <italic>NDC80</italic> was observed in 131 patients (high-risk) (35.30%) and a low expression was observed in 143 patients (38.54%) (low-risk). Similarly, a high expression of <italic>DLGAP5</italic> was observed in 134 patients (high-risk) (36.11%) and a low expression was observed in 136 patients (low-risk) (36.65%). The effects of <italic>NDC80</italic> and <italic>DLGAP5</italic> gene expression on the survival of these patients are presented in <xref rid="tII-WASJ-6-6-00268" ref-type="table">Table II</xref>. The results suggested that only <italic>NDC80</italic> had a significant effect on both the OS and DFS of patients with liver cancer (<xref rid="tII-WASJ-6-6-00268" ref-type="table">Table II</xref>).</p>
<p>Subsequently, the data of five common genes (<italic>MCM2</italic>, <italic>ORC1</italic>, <italic>CDC45</italic>, <italic>MCM3</italic> and <italic>TOP2A</italic>) identified by TCGA data analysis of cervical and liver cancer were validated using the c-BioPortal database. Of these five genes, only <italic>MCM3</italic>, <italic>CDC45</italic> and <italic>ORC1</italic> were found to exert significant effects on both the OS and DFS of patients with liver cancer (<xref rid="tIII-WASJ-6-6-00268" ref-type="table">Table III</xref>). None of these genes significantly affected the survival rate of patients with cervical cancer.</p>
<p>In addition, ROC analysis was performed for these four genes (<italic>MCM3</italic>, <italic>NDC80</italic>, <italic>CDC45</italic> and <italic>ORC1</italic>), which were found to exert a significant effect on both the OS and DFS of patients with liver cancer. The results suggested that out of these genes, only <italic>CDC45</italic> (<xref rid="SD1-WASJ-6-6-00268" ref-type="supplementary-material">Fig. S1A</xref>) and <italic>ORC1</italic> (<xref rid="SD1-WASJ-6-6-00268" ref-type="supplementary-material">Fig. S1B</xref>) had comparatively high area under the curve (AUC) values (0.57) compared with <italic>NDC80</italic> (<xref rid="SD1-WASJ-6-6-00268" ref-type="supplementary-material">Fig. S1C</xref>) and <italic>MCM3</italic> (AUC &lt;0.43; <xref rid="SD1-WASJ-6-6-00268" ref-type="supplementary-material">Fig. S1D</xref>).</p>
</sec>
<sec>
<title>Molecular models and molecular docking of common DEGs with inhibitors</title>
<p>AlphaFold was used [AlphaFold Protein Structure Database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ebi.ac.uk">ebi.ac.uk</ext-link>)] to produce the tertiary structure of DEGs expressed in tumor samples through <italic>in silico</italic> projection processing of their molecular structures. Using the CMap online portal, we identified 48 inhibitors that inhibit common genes. However, the structures of 13 inhibitors were not available in the PubChem database. No inhibitors of <italic>MCM2</italic>, <italic>MCM3</italic>, <italic>CDC45</italic> and <italic>ORC1</italic> were found. The binding affinities of the 35 inhibitors to the remaining common genes (<italic>NDC80</italic>, <italic>DLGAP5</italic> and <italic>TOP2A</italic>) are presented in <xref rid="SD7-WASJ-6-6-00268" ref-type="supplementary-material">Table SV</xref>. The inhibitor (cytochalasin B) with the highest binding affinity, was selected for MD simulations.</p>
</sec>
<sec>
<title>MD simulations</title>
<p>The RMSD of the backbone atoms was used to analyze the stability of the complex, as shown in <xref rid="f8-WASJ-6-6-00268" ref-type="fig">Fig. 8A</xref>. The average RMSD of the complex (<italic>NDC80</italic> and cytochalasin B) was 1.32±0.25 (8A). Furthermore, the RMSF for the <italic>NDC80</italic>-cytochalasin B complex were calculated. In the RMSF plot, residues of <italic>NDC80</italic> and the cytochalasin B complex were found to have fewer fluctuations (average, 0.81±0.12 SEM) (<xref rid="f8-WASJ-6-6-00268" ref-type="fig">Fig. 8B</xref>). Protein compactness was assessed by plotting the radius of gyration (Rg) (<xref rid="f8-WASJ-6-6-00268" ref-type="fig">Fig. 8C</xref>). The Rg plot revealed the stability and compactness of the docked complex. The average value of the radius of gyration was 28.78±0.20 A˚ and it remained stable after 20 nsec, indicating the stability of the 3D protein structure during MD simulation. The results also revealed that the electrostatic (-888±90.72) and van der Waals energies (-347±16.96) of the docked complex were negative, which ultimately resulted in a negative binding energy (-122±6.25 kcal/mol). These results suggest that cytochalasin B can be used as a therapeutic drug in cancers where a high expression of <italic>NDC80</italic> significantly affects the survival of patients.</p>
</sec>
<sec>
<title>Identification of unique biomarkers based on DEGs in liver, lung, cervical and pancreatic cancers</title>
<p>TCGA data analysis demonstrated that 58.40% (3393/5809), 41.51% (1263/3042), 67.24% (4037/6003) and 21.95% (9/41) DEGs were only present in the lungs, cervical, liver and pancreatic tumors, respectively, and were absent in other tumors. Furthermore, these genes were filtered based on their impact on the survival of patients with cancer. It was observed that only three, eight and 23 genes significantly affected the survival of patients with lung, cervical and liver tumors, respectively (<xref rid="tIV-WASJ-6-6-00268" ref-type="table">Table IV</xref>). The impact of these genes on the survival of patients with these cancers differed (<xref rid="SD8-WASJ-6-6-00268" ref-type="supplementary-material">Table SVI</xref>). These genes were then validated using c-BioPortal data of the specific cancer type. In lung cancer, none of the three genes had a significant effect on OS or DFS. In cervical cancer, out of the eight genes, the data for only six genes were available in the c-BioPortal database [Fanconi anemia complementation group M (<italic>FANCM)</italic>, ubiquitin-specific peptidase 18 <italic>(USP18)</italic>, colony stimulating factor 2 <italic>(CSF2)</italic>, DnaJ heat shock protein family (Hsp40) member <italic>C9 (DNAJC9)</italic>, fatty acid synthase <italic>(FASN)</italic> and Runt-related transcription factor 1 <italic>(RUNX1</italic>]. Notably, all patients with cervical cancer exhibited a high expression of CSF2 on the basis of cut-off value. Of the remaining five genes, only <italic>FASN</italic> was found to exert a significant impact on both the OS and DFS of patients with cervical cancer (<xref rid="tV-WASJ-6-6-00268" ref-type="table">Table V</xref>). Similarly, the expression of cytochrome P450 family 2 subfamily C member 9 (<italic>CYP2C9)</italic> and acyl-CoA dehydrogenase short chain (<italic>ACADS)</italic> in patients with liver cancer had a significant effect on both the OS and DFS.</p>
</sec>
<sec>
<title>Recurrence analysis</title>
<p>Recurrence analysis was performed only for <italic>FASN</italic> in cervical cancer, and for <italic>CYP2C9</italic> and <italic>ACADS</italic> in patients with liver cancer. For the recurrence analysis, subjects with no follow-up data and recurrence status were excluded. The AUC value of <italic>FASN</italic> was 0.57, and the AUC value of <italic>CYP2C9</italic> and <italic>ACADS</italic> was 0.56 and 0.59, respectively. Due to the low number of patients with stage II, III and IV diseases, both the patients with cervical and liver cancer were divided into two groups. Group I included all patients with stage I cancer (low risk), and group II included all other remaining patients with stage II, III or IV cancer (high risk). ROC analysis was conducted using OriginPro statistical software, and the AUC value was calculated. A total of 66 patients with cervical cancer had AJCC stage I tumors, while 52 patients were classified as either stage II, III, or stage IV. Combining the gene expression of <italic>FASN</italic> with tumor stage in cervical cancer slightly decreased the AUC value (0.56). These results suggest that tumor stage does not play a significant role in the recurrence of cervical cancer. A total of 265 patients with liver cancer had stage I tumors, while 69 patients had stage II, III, or IV tumors. Combining <italic>CYP2C9</italic> and <italic>ACADS</italic> expression with TNM stage enhanced the AUC value to 0.71 in liver cancer, suggesting that the expression of these genes together with tumor stage can be used as prognostic markers for liver cancer recurrence (<xref rid="b39-WASJ-6-6-00268" ref-type="bibr">39</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p>Surgery, radiotherapy and chemotherapy are the standard treatments for the types of cancer examined in the present study. However, in recent years, treatments targeting specific genes or proteins have also been used for cancer treatment, especially in cases of metastatic disease. For example, monoclonal antibodies targeting specific receptors, such as bevacizumab (avastin), are used in non-small cell lung carcinoma and cervical cancer (<xref rid="b40-WASJ-6-6-00268" ref-type="bibr">40</xref>), whereas nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, and tremelimumab/durvalumab are used for hepatocellular carcinoma (<xref rid="b41-WASJ-6-6-00268" ref-type="bibr">41</xref>). None of the monoclonal antibodies have been approved for pancreatic cancer. However, no significant difference in the OS of patients has been found in recent years compared to previous years. For example, it was shown that the OS of avastin-treated patients with lung cancer was 18.5 months in 2014(<xref rid="b42-WASJ-6-6-00268" ref-type="bibr">42</xref>) and 16.3 months in 2021(<xref rid="b43-WASJ-6-6-00268" ref-type="bibr">43</xref>). Hence, the management of recurrence and OS remains a challenge in the field of cancer therapeutics. Therefore, it is critical to identify survival-related biomarkers that can be subsequently used to separate patients into high- or low-risk groups to enhance treatment efficacy.</p>
<p>The present study focused on genes affecting the OS and DFS of patients with four types of cancer. A dataset from TCGA for these types of cancer was used to identify the DEGs. Liver and pancreatic cancers had the largest and smallest number of DEGs, respectively. The present study identified the top 70 DEGs that were common in the three types of cancer, excluding pancreatic cancer. Of these 70 common genes, only a few genes in each cancer type had a significant impact on OS. For instance, only two genes (DLGAP4 and <italic>NDC80</italic>) in liver and lung cancer and five genes (<italic>MCM2</italic>, <italic>MCM3</italic>, <italic>ORC1</italic>, <italic>CDC45</italic> and <italic>TOP2A</italic>) in liver and cervical cancer were common, which significantly affected the OS of patients with cancer. These common genes have also been reported previously. For example, DLGAP4 and <italic>NDC80</italic> act as effective prognostic markers for liver and lung cancers, and are closely related to tumor progression and metastasis (<xref rid="b44-WASJ-6-6-00268 b45-WASJ-6-6-00268 b46-WASJ-6-6-00268 b47-WASJ-6-6-00268 b48-WASJ-6-6-00268" ref-type="bibr">44-48</xref>). <italic>DLGAP5</italic> is a microtubule-associated protein that plays an oncogenic role in tumorigenesis, including lung cancer and hepatocellular carcinoma (<xref rid="b49-WASJ-6-6-00268" ref-type="bibr">49</xref>). For instance, it has been shown that the high expression of DLGAL5 is associated with a poor response to immunotherapy and promotes proliferation via cell cycle-related pathways in lung cancer, such as p53 and DNA replication (<xref rid="b46-WASJ-6-6-00268" ref-type="bibr">46</xref>). Similarly, the OS of patients with hepatocellular carcinoma exhibiting a high expression of DLGAP5 has been found to be low (<xref rid="b45-WASJ-6-6-00268" ref-type="bibr">45</xref>). It has also been shown that <italic>PRC1</italic> and <italic>DLGAP5</italic> are co-expressed in proliferative T-cells that actively participate in immune escape by liver cancer cells and thereby are independent risk factors for poor survival (<xref rid="b50-WASJ-6-6-00268" ref-type="bibr">50</xref>). These studies suggest that DLGAP5 plays a key role in suppressing the immune response to immunotherapy, and thus, inhibitors targeting DLGAP5 along with immunotherapy may enhance the immune response to immunotherapy. <italic>NDC80</italic> (also known as Hec1), a fundamental component of the outer kinetochore and mitotic regulator, is of particular relevance, as it has a demonstrable link with cancer progression (<xref rid="b47-WASJ-6-6-00268" ref-type="bibr">47</xref>). For example, a high <italic>NDC80</italic> expression has been found to be associated with the poor survival of patients with hepatocellular carcinoma and liver cancer cell lines (<xref rid="b51-WASJ-6-6-00268" ref-type="bibr">51</xref>). The silencing of <italic>NDC80</italic> has been shown to significantly reduce hepatic cancer cell proliferation, colony formation, increased apoptosis, cell cycle arrest at the S-phase and hepatitis B virus-related hepatocellular carcinoma (<xref rid="b47-WASJ-6-6-00268" ref-type="bibr">47</xref>,<xref rid="b52-WASJ-6-6-00268" ref-type="bibr">52</xref>). Similarly, the increased expression of <italic>NDC80</italic> has been shown to induce therapeutic radioresistance by promoting autophagy in lung cancer (<xref rid="b48-WASJ-6-6-00268" ref-type="bibr">48</xref>). These studies suggest the significance of <italic>NDC80</italic> silencing or inhibition in reducing cancer proliferation and therapeutic resistance. The results of the present study also suggest that the expression of <italic>DLGAP5</italic> and <italic>NDC80</italic> are significantly increased in both liver and lung cancer. However, the results of GEPIA2 analysis demonstrated that the high expression of these two genes enhanced the survival of patients with lung cancer, while reducing the OS of patients with liver cancer patients. The opposite role of these genes in lung and liver cancer may be due to various factors, such as intracellular location of genes and associated mechanisms, which might affect drug sensitivity and thus, survival in these cancer patients. In the present study, it was observed that cytochalasin B was a potent NDC80 inhibitor that can be used to enhance the survival of patients with cancer, where a high expression contributes to poor survival.</p>
<p>The expression of <italic>MCM2</italic>, <italic>MCM3</italic>, <italic>ORC1</italic>, <italic>CDC45</italic> and <italic>TOP2A</italic> has also been shown to be significantly increased in liver and cervical cancers (<xref rid="b37-WASJ-6-6-00268" ref-type="bibr">37</xref>,<xref rid="b53-WASJ-6-6-00268 b54-WASJ-6-6-00268 b55-WASJ-6-6-00268 b56-WASJ-6-6-00268 b57-WASJ-6-6-00268 b58-WASJ-6-6-00268 b59-WASJ-6-6-00268 b60-WASJ-6-6-00268" ref-type="bibr">53-60</xref>). These genes are involved in DNA replication and cell cycle (<xref rid="b58-WASJ-6-6-00268" ref-type="bibr">58</xref>,<xref rid="b60-WASJ-6-6-00268 b61-WASJ-6-6-00268 b62-WASJ-6-6-00268 b63-WASJ-6-6-00268" ref-type="bibr">60-63</xref>). It was found that all five genes were common in liver and cervical cancer, and the expression of these genes significantly affected the survival of both cancers. The results of the GEPIA2 analysis demonstrated the opposite effect on survival in patients with liver and cervical cancer. For example, the OS of patients with cervical cancer exhibiting high transcript per million of these genes was high, whereas the opposite results were observed for patients with liver cancer. Additionally, all seven common genes only affected DFS in the case of liver cancer. Several anticancer drugs, such as pembrolizumab, entrectinib and larotrectinib have been used in clinical settings to treat tumors with common molecular features (<xref rid="b64-WASJ-6-6-00268" ref-type="bibr">64</xref>). Furthermore, pharmacogenomics-guided therapeutic decisions help enhance the precision of cancer therapy and improve the outcomes of patients in clinical practice. However, the present study suggests that although the common genes may be used for the diagnosis or prognosis of patients with cancer, they should be used to identify the risk of cancer or for therapeutic intervention only after verifying their role in cancer survival. This is due to the reason that although the genes could be differentially expressed at the significant level, they may not significantly affect survival. Moreover, the effect of specific genes on survival may vary depending on cancer type. After validating TCGA data with the data from the c-BioPortal database, it was suggested that only two genes, <italic>CDC45</italic> and <italic>ORC1</italic>, can be used for the prognosis of patients with liver cancer progression due to their effects on OS and DFS, and a comparatively high AUC value.</p>
<p>The present study also identified three, eight and 23 unique DEGs in lung, cervical and liver tumors, respectively, which had a significant effect on survival. These genes are unique and are only present in specific types of cancer. To determine whether these DEGs could be used for the survival prediction of these cancers, the data were validated using the cBioPortal database. <italic>FASN</italic> has been found to be associated with several hallmarks of cancer and to promote cell proliferation through membrane biosynthesis. A high gene expression has been observed in advanced stages of cervical cancer, and it has been shown that the use of a <italic>FASN</italic> inhibitor arrests the cell cycle and autophagy in cervical cancer (<xref rid="b65-WASJ-6-6-00268" ref-type="bibr">65</xref>). The present study also observed a high expression of <italic>FASN</italic> and its association with both OS and DFS. However, due to its low ROC value, this gene cannot be used for the diagnosis or prognosis of patients with cervical cancer. The results support the protein atlas data, where the expression of <italic>FASN</italic> was not considered a prognostic biomarker in cervical cancer. CYP2C9 is an enzyme that is involved in drug metabolism. Hypoxia-inducible CYP2C9 enhances drug resistance in liver cancer stem cells (<xref rid="b66-WASJ-6-6-00268" ref-type="bibr">66</xref>). <italic>ACADS</italic> encodes key metabolic enzymes that are associated with the metabolic reactions involved in liver cancer proliferation and metastasis and is highly likely that <italic>ACADS</italic> could be a novel therapeutic target in liver cancer (<xref rid="b67-WASJ-6-6-00268" ref-type="bibr">67</xref>). According to the protein atlas, both <italic>CYP2C9</italic> and <italic>ACADS</italic> can be used as prognostic markers for liver cancer. The present study also observed that <italic>CYP2C9</italic> and <italic>ACADS</italic> in liver cancer significantly affected the OS and DFS of patients. Previous studies have demonstrated that tumor stage and a combination of biomarker panels can better predict the prognosis of recurrence or survival (<xref rid="b68-WASJ-6-6-00268" ref-type="bibr">68</xref>,<xref rid="b69-WASJ-6-6-00268" ref-type="bibr">69</xref>). Therefore, the present study analyzed the effects of these genes together with the AJCC pathological staging on cancer recurrence. It was suggested that the expression of <italic>CYP2C9</italic> and <italic>ACADS</italic>, together with tumor stage, may be used as prognostic markers for liver cancer recurrence due to their comparatively higher ROC values (vs. other genes). However, furthers investigation of the site identification of DEGs are required, which may lead to the discovery of specific targeted drugs and more precise targeted therapy.</p>
<p>In conclusion, the present study identified two common genes in liver and lung cancers, and five common genes in liver and cervical cancers. However, only two common genes, <italic>CDC45</italic> and <italic>ORC1</italic>, can be used for the prognosis of liver cancer owing to their effects on OS, DFS and comparatively higher AUC values. Similarly, three, eight and 23 genes were unique to lung, cervical and liver tumors, respectively. However, when these data were validated using the cBioPortal dataset, it was identified that only the <italic>CYP2C9</italic> and <italic>ACADS</italic> genes, along with tumor stage, could be used for the prognosis or diagnosis of recurrence in liver cancer when compared with lung and cervical cancer. However, the present study did not measure the expression of DEGs at translational levels in either of the cancers examined. Thus, this is a limitation of the present study. In future studies, the authors aim to investigate the expression of common genes at both the transcriptional and translational labels in all the types of cancer examined herein.</p>
<p>It is suggested that the identification of therapeutic targets in future studies should focus on DEGs and their impact on survival, cancer type and stage. The reason for this is that the genes can be differentially expressed at significant levels, but they may not significantly affect survival or recurrence.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="SD1-WASJ-6-6-00268" content-type="local-data">
<caption>
<title>AUC curve of (A) <italic>CDC45</italic>, (B) <italic>ORC1</italic>, (C) <italic>NDC80</italic>, and (D) <italic>MCM3</italic> in samples from patients with liver cancer. AUC, area under the curve; <italic>CDC45</italic>, <italic>cell division cycle 45; ORC1</italic>, <italic>origin recognition complex subunit 1; NDC80</italic>, <italic>human NDC80 kinetochore complex component; MCM3</italic>, <italic>human minichromosome maintenance complex component 3</italic>.</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data1.pdf"/>
</supplementary-material>
<supplementary-material id="SD2-WASJ-6-6-00268" content-type="local-data">
<caption>
<title>AUC curve of (A) <italic>FASN alone and with tumor stages</italic> in cervical cancer (B) <italic>CYP2C9</italic>, ACADS alone and with tumor stages in liver cancer. AUC, area under the curve; <italic>CYP2C9</italic>, <italic>cytochrome P450 family 2 subfamily C member 9</italic>; <italic>ACADS</italic>, acyl-CoA dehydrogenase short chain.</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data1.pdf"/>
</supplementary-material>
<supplementary-material id="SD3-WASJ-6-6-00268" content-type="local-data">
<caption>
<title>Significant differentially expressed genes in lung, liver, cervical and pancreatic cancer.</title>
</caption>
<media mimetype="application" mime-subtype="xls" xlink:href="Supplementary_Data2.xlsx"/>
</supplementary-material>
<supplementary-material id="SD4-WASJ-6-6-00268" content-type="local-data">
<caption>
<title>Top 70 common hub genes that are expressed in lung, cervical and liver cancer.</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data3.pdf"/>
</supplementary-material>
<supplementary-material id="SD5-WASJ-6-6-00268" content-type="local-data">
<caption>
<title>Go function and pathway enrichment analysis of seven common genes in lung, cervical and liver cancer.</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data3.pdf"/>
</supplementary-material>
<supplementary-material id="SD6-WASJ-6-6-00268" content-type="local-data">
<caption>
<title>KEGG pathways analysis of seven common genes in lung, cervical, and liver cancer.</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data3.pdf"/>
</supplementary-material>
<supplementary-material id="SD7-WASJ-6-6-00268" content-type="local-data">
<caption>
<title>Binding affinity of inhibitors with the common genes present in at least two types of cancer.</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data3.pdf"/>
</supplementary-material>
<supplementary-material id="SD8-WASJ-6-6-00268" content-type="local-data">
<caption>
<title>Effects of the high expression of unique DEGs on the survival of patients with lung, cervical and liver cancer.</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data3.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors' contributions</title>
<p>PS, NK and DB performed all the analyses. PS, MP and SKP performed the experimental work on the patient samples. RG was responsible for the conceptualization of the study and for the drafting of the manuscript. PS and RG confirm the authenticity of all the raw data. All the authors have read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>The present study was approved by the Ethics Committee of Parul University (PUIECHR/PIMSR/00/081734/5307). All methods were performed according to the relevant guidelines and regulations provided by the Ethics Committee of Parul University. Informed consent was obtained from all the participants to participate in the study.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-WASJ-6-6-00268"><label>1</label><element-citation publication-type="journal"><comment>World Health Organization (WHO): Global health estimates 2020: Deaths by cause, age, sex, by country and by region, 2000-2019. WHO, Geneva, 2019.</comment></element-citation></ref>
<ref id="b2-WASJ-6-6-00268"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><volume>71</volume><fpage>209</fpage><lpage>249</lpage><year>2021</year><pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id></element-citation></ref>
<ref id="b3-WASJ-6-6-00268"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Ai</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Identification of potential diagnostic and prognostic biomarkers for colorectal cancer based on GEO and TCGA databases</article-title><source>Front Genet</source><volume>11</volume><issue>602922</issue><year>2020</year><pub-id pub-id-type="pmid">33519906</pub-id><pub-id pub-id-type="doi">10.3389/fgene.2020.602922</pub-id></element-citation></ref>
<ref id="b4-WASJ-6-6-00268"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathishkumar</surname><given-names>K</given-names></name><name><surname>Chaturvedi</surname><given-names>M</given-names></name><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Stephen</surname><given-names>S</given-names></name><name><surname>Mathur</surname><given-names>P</given-names></name></person-group><article-title>Cancer incidence estimates for 2022 &amp; projection for 2025: Result from national cancer registry programme, India</article-title><source>Indian J Med Res</source><volume>156</volume><fpage>598</fpage><lpage>607</lpage><year>2022</year><pub-id pub-id-type="pmid">36510887</pub-id><pub-id pub-id-type="doi">10.4103/ijmr.ijmr_1821_22</pub-id></element-citation></ref>
<ref id="b5-WASJ-6-6-00268"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>PW</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Kong</surname><given-names>XY</given-names></name><name><surname>Cai</surname><given-names>YD</given-names></name></person-group><article-title>Classifying ten types of major cancers based on reverse phase protein array profiles</article-title><source>PLoS One</source><volume>10</volume><issue>e0123147</issue><year>2015</year><pub-id pub-id-type="pmid">25822500</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0123147</pub-id></element-citation></ref>
<ref id="b6-WASJ-6-6-00268"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Gang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Xin</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name></person-group><article-title>Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer</article-title><source>BMC Cancer</source><volume>21</volume><issue>791</issue><year>2021</year><pub-id pub-id-type="pmid">34238253</pub-id><pub-id pub-id-type="doi">10.1186/s12885-021-08520-1</pub-id></element-citation></ref>
<ref id="b7-WASJ-6-6-00268"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liao</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Identification of key genes and biological pathways in Chinese lung cancer population using bioinformatics analysis</article-title><source>PeerJ</source><volume>10</volume><issue>e12731</issue><year>2022</year><pub-id pub-id-type="pmid">35178291</pub-id><pub-id pub-id-type="doi">10.7717/peerj.12731</pub-id></element-citation></ref>
<ref id="b8-WASJ-6-6-00268"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HJ</given-names></name><name><surname>Xue</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wan</surname><given-names>LH</given-names></name><name><surname>Zhu</surname><given-names>YX</given-names></name></person-group><article-title>Identification of key genes and pathways of diagnosis and prognosis in cervical cancer by bioinformatics analysis</article-title><source>Mol Genet Genomic Med</source><volume>8</volume><issue>e1200</issue><year>2020</year><pub-id pub-id-type="pmid">32181600</pub-id><pub-id pub-id-type="doi">10.1002/mgg3.1200</pub-id></element-citation></ref>
<ref id="b9-WASJ-6-6-00268"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>LY</given-names></name><name><surname>Huang</surname><given-names>HY</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>JY</given-names></name><name><surname>Hao</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Xie</surname><given-names>YX</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>YH</given-names></name><name><surname>Zeng</surname><given-names>L</given-names></name></person-group><article-title>A prognostic survival model of pancreatic adenocarcinoma based on metabolism-related gene expression</article-title><source>Front Genet</source><volume>13</volume><issue>804190</issue><year>2022</year><pub-id pub-id-type="pmid">35664305</pub-id><pub-id pub-id-type="doi">10.3389/fgene.2022.804190</pub-id></element-citation></ref>
<ref id="b10-WASJ-6-6-00268"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>LK</given-names></name><name><surname>Yuan</surname><given-names>HY</given-names></name><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Bai</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title>Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer</article-title><source>World J Clin Cases</source><volume>11</volume><fpage>4763</fpage><lpage>4787</lpage><year>2023</year><pub-id pub-id-type="pmid">37584004</pub-id><pub-id pub-id-type="doi">10.12998/wjcc.v11.i20.4763</pub-id></element-citation></ref>
<ref id="b11-WASJ-6-6-00268"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>KD</given-names></name><name><surname>Vora</surname><given-names>HH</given-names></name><name><surname>Patel</surname><given-names>PS</given-names></name></person-group><article-title>Transcriptional biomarkers in oral cancer: An integrative analysis and the cancer genome atlas validation</article-title><source>Asian Pac J Cancer Prev</source><volume>22</volume><fpage>371</fpage><lpage>380</lpage><year>2021</year><pub-id pub-id-type="pmid">33639650</pub-id><pub-id pub-id-type="doi">10.31557/APJCP.2021.22.2.371</pub-id></element-citation></ref>
<ref id="b12-WASJ-6-6-00268"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veyel</surname><given-names>D</given-names></name><name><surname>Wenger</surname><given-names>K</given-names></name><name><surname>Broermann</surname><given-names>A</given-names></name><name><surname>Bretschneider</surname><given-names>T</given-names></name><name><surname>Luippold</surname><given-names>AH</given-names></name><name><surname>Krawczyk</surname><given-names>B</given-names></name><name><surname>Rist</surname><given-names>W</given-names></name><name><surname>Simon</surname><given-names>E</given-names></name></person-group><article-title>Biomarker discovery for chronic liver diseases by multi-omics-a preclinical case study</article-title><source>Sci Rep</source><volume>10</volume><issue>1314</issue><year>2020</year><pub-id pub-id-type="pmid">31992752</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-58030-6</pub-id></element-citation></ref>
<ref id="b13-WASJ-6-6-00268"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Identidication of novel biomarkers in non-small cell lung cancer using machine learning</article-title><source>Sci Rep</source><volume>12</volume><issue>16693</issue><year>2022</year><pub-id pub-id-type="pmid">36202977</pub-id><pub-id pub-id-type="doi">10.1038/s41598-022-21050-5</pub-id></element-citation></ref>
<ref id="b14-WASJ-6-6-00268"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname><given-names>RS</given-names></name><name><surname>Stoita</surname><given-names>A</given-names></name></person-group><article-title>Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?</article-title><source>World J Gastroenterol</source><volume>27</volume><fpage>4045</fpage><lpage>4087</lpage><year>2021</year><pub-id pub-id-type="pmid">34326612</pub-id><pub-id pub-id-type="doi">10.3748/wjg.v27.i26.4045</pub-id></element-citation></ref>
<ref id="b15-WASJ-6-6-00268"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kori</surname><given-names>M</given-names></name><name><surname>Arga</surname><given-names>KY</given-names></name></person-group><article-title>Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective</article-title><source>PLoS One</source><volume>13</volume><issue>e0200717</issue><year>2018</year><pub-id pub-id-type="pmid">30020984</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0200717</pub-id></element-citation></ref>
<ref id="b16-WASJ-6-6-00268"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Ng</surname><given-names>TK</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Gan</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name></person-group><article-title>Circulating exosomal CPNE3 as a diagnostic and prognostic biomarker for colorectal cancer</article-title><source>J Cell Physiol</source><volume>234</volume><fpage>1416</fpage><lpage>1425</lpage><year>2019</year><pub-id pub-id-type="pmid">30078189</pub-id><pub-id pub-id-type="doi">10.1002/jcp.26936</pub-id></element-citation></ref>
<ref id="b17-WASJ-6-6-00268"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>B</given-names></name><name><surname>Zhuang</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Qiao</surname><given-names>H</given-names></name></person-group><article-title>Identification of biomarkers based on differentially expressed genes in papillary thyroid carcinoma</article-title><source>Sci Rep</source><volume>8</volume><issue>9912</issue><year>2018</year><pub-id pub-id-type="pmid">29967488</pub-id><pub-id pub-id-type="doi">10.1038/s41598-018-28299-9</pub-id></element-citation></ref>
<ref id="b18-WASJ-6-6-00268"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neary</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>P</given-names></name></person-group><article-title>Identifying gene expression patterns associated with drug-specific survival in cancer patients</article-title><source>Sci Rep</source><volume>11</volume><issue>5004</issue><year>2021</year><pub-id pub-id-type="pmid">33654134</pub-id><pub-id pub-id-type="doi">10.1038/s41598-021-84211-y</pub-id></element-citation></ref>
<ref id="b19-WASJ-6-6-00268"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>TC</given-names></name><name><surname>Olsen</surname><given-names>C</given-names></name><name><surname>Garofano</surname><given-names>L</given-names></name><name><surname>Cava</surname><given-names>C</given-names></name><name><surname>Garolini</surname><given-names>D</given-names></name><name><surname>Sabedot</surname><given-names>TS</given-names></name><name><surname>Malta</surname><given-names>TM</given-names></name><name><surname>Pagnotta</surname><given-names>SM</given-names></name><name><surname>Castiglioni</surname><given-names>I</given-names></name><etal/></person-group><article-title>TCGAbiolinks: An R/Bioconductor package for integrative analysis of TCGA data</article-title><source>Nucleic Acids Res</source><volume>44</volume><issue>e71</issue><year>2016</year><pub-id pub-id-type="pmid">26704973</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkv1507</pub-id></element-citation></ref>
<ref id="b20-WASJ-6-6-00268"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><volume>15</volume><issue>550</issue><year>2014</year><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref>
<ref id="b21-WASJ-6-6-00268"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Mering</surname><given-names>C</given-names></name><name><surname>Huynen</surname><given-names>M</given-names></name><name><surname>Jaeggi</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Snel</surname><given-names>B</given-names></name></person-group><article-title>STRING: A database of predicted functional associations between proteins</article-title><source>Nucleic Acids Res</source><volume>31</volume><fpage>258</fpage><lpage>261</lpage><year>2003</year><pub-id pub-id-type="pmid">12519996</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkg034</pub-id></element-citation></ref>
<ref id="b22-WASJ-6-6-00268"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name></person-group><article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title><source>Bioinformatics</source><volume>32</volume><fpage>2847</fpage><lpage>2849</lpage><year>2016</year><pub-id pub-id-type="pmid">27207943</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btw313</pub-id></element-citation></ref>
<ref id="b23-WASJ-6-6-00268"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses</article-title><source>Nucleic Acids Res</source><volume>45</volume><fpage>W98</fpage><lpage>W102</lpage><year>2017</year><pub-id pub-id-type="pmid">28407145</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id></element-citation></ref>
<ref id="b24-WASJ-6-6-00268"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis</article-title><source>Nucleic Acids Res</source><volume>47</volume><fpage>W556</fpage><lpage>W560</lpage><year>2019</year><pub-id pub-id-type="pmid">31114875</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkz430</pub-id></element-citation></ref>
<ref id="b25-WASJ-6-6-00268"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jaehnig</surname><given-names>EJ</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs</article-title><source>Nucleic Acids Res</source><volume>47</volume><fpage>W199</fpage><lpage>W205</lpage><year>2019</year><pub-id pub-id-type="pmid">31114916</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkz401</pub-id></element-citation></ref>
<ref id="b26-WASJ-6-6-00268"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picot</surname><given-names>E</given-names></name><name><surname>Jouan</surname><given-names>R</given-names></name><name><surname>Bach</surname><given-names>E</given-names></name><name><surname>Murcier</surname><given-names>G</given-names></name><name><surname>Borgnat</surname><given-names>F</given-names></name></person-group><article-title>Oral metastasis of pulmonary adenocarcinoma: Diagnosis and treatment</article-title><source>J Oral Med Oral Surg</source><volume>25</volume><fpage>9</fpage><lpage>12</lpage><year>2019</year></element-citation></ref>
<ref id="b27-WASJ-6-6-00268"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name></person-group><article-title>The risk and prognostic factors for lung metastases in oral squamous cell carcinoma: A population-based analysis of the SEER database</article-title><source>J Stomatol Oral Maxillofac Surg</source><volume>125</volume><issue>101713</issue><year>2024</year><pub-id pub-id-type="pmid">38040119</pub-id><pub-id pub-id-type="doi">10.1016/j.jormas.2023.101713</pub-id></element-citation></ref>
<ref id="b28-WASJ-6-6-00268"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>KM</given-names></name></person-group><article-title>Prognosis of hepatocellular carcinoma metastasizing to the oral cavity</article-title><source>Maxillofac Plast Reconstr Surg</source><volume>43</volume><issue>9</issue><year>2021</year><pub-id pub-id-type="pmid">33689049</pub-id><pub-id pub-id-type="doi">10.1186/s40902-021-00294-7</pub-id></element-citation></ref>
<ref id="b29-WASJ-6-6-00268"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>SR</given-names></name><name><surname>Shankar</surname><given-names>YU</given-names></name><name><surname>Rastogi</surname><given-names>V</given-names></name><name><surname>Maragathavalli</surname><given-names>G</given-names></name></person-group><article-title>Metastatic hepatocellular carcinoma in the maxilla and mandible, an extremely rare presentation</article-title><source>Contemp Clin Dent</source><volume>6</volume><fpage>S117</fpage><lpage>S121</lpage><year>2015</year><pub-id pub-id-type="pmid">25821363</pub-id><pub-id pub-id-type="doi">10.4103/0976-237X.152966</pub-id></element-citation></ref>
<ref id="b30-WASJ-6-6-00268"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pires</surname><given-names>RS</given-names></name><name><surname>Sagarra</surname><given-names>R</given-names></name><name><surname>Corrêa</surname><given-names>ME</given-names></name><name><surname>Pereira</surname><given-names>CM</given-names></name><name><surname>Vargas</surname><given-names>PA</given-names></name><name><surname>Lopes</surname><given-names>MA</given-names></name></person-group><article-title>Oral metastasis of a hepatocellular carcinoma</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><volume>97</volume><fpage>359</fpage><lpage>368</lpage><year>2004</year><pub-id pub-id-type="pmid">15024361</pub-id><pub-id pub-id-type="doi">10.1016/S1079210403006127</pub-id></element-citation></ref>
<ref id="b31-WASJ-6-6-00268"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Vaught</surname><given-names>L</given-names></name><name><surname>Grosche</surname><given-names>A</given-names></name><name><surname>Okunieff</surname><given-names>P</given-names></name><name><surname>Vidyasagar</surname><given-names>S</given-names></name></person-group><article-title>An amino acid-based oral rehydration solution (AA-ORS) enhanced intestinal epithelial proliferation in mice exposed to radiation</article-title><source>Sci Rep</source><volume>6</volume><issue>37220</issue><year>2016</year><pub-id pub-id-type="pmid">27876791</pub-id><pub-id pub-id-type="doi">10.1038/srep37220</pub-id></element-citation></ref>
<ref id="b32-WASJ-6-6-00268"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><volume>25</volume><fpage>402</fpage><lpage>408</lpage><year>2001</year><pub-id pub-id-type="pmid">11846609</pub-id><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id></element-citation></ref>
<ref id="b33-WASJ-6-6-00268"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youens-Clark</surname><given-names>K</given-names></name><name><surname>Faga</surname><given-names>B</given-names></name><name><surname>Yap</surname><given-names>IV</given-names></name><name><surname>Stein</surname><given-names>L</given-names></name><name><surname>Ware</surname><given-names>D</given-names></name></person-group><article-title>CMap 1.01: A comparative mapping application for the internet</article-title><source>Bioinformatics</source><volume>25</volume><fpage>3040</fpage><lpage>3042</lpage><year>2009</year><pub-id pub-id-type="pmid">19648141</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btp458</pub-id></element-citation></ref>
<ref id="b34-WASJ-6-6-00268"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallakyan</surname><given-names>S</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><article-title>Small-molecule library screening by docking with PyRx</article-title><source>Methods Mol Biol</source><volume>1263</volume><fpage>243</fpage><lpage>250</lpage><year>2015</year><pub-id pub-id-type="pmid">25618350</pub-id><pub-id pub-id-type="doi">10.1007/978-1-4939-2269-7_19</pub-id></element-citation></ref>
<ref id="b35-WASJ-6-6-00268"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>JC</given-names></name><name><surname>Hardy</surname><given-names>DJ</given-names></name><name><surname>Maia</surname><given-names>JDC</given-names></name><name><surname>Stone</surname><given-names>JE</given-names></name><name><surname>Ribeiro</surname><given-names>JV</given-names></name><name><surname>Bernardi</surname><given-names>RC</given-names></name><name><surname>Buch</surname><given-names>R</given-names></name><name><surname>Fiorin</surname><given-names>G</given-names></name><name><surname>Hénin</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Scalable molecular dynamics on CPU and GPU architectures with NAMD</article-title><source>J Chem Phys</source><volume>153</volume><issue>044130</issue><year>2020</year><pub-id pub-id-type="pmid">32752662</pub-id><pub-id pub-id-type="doi">10.1063/5.0014475</pub-id></element-citation></ref>
<ref id="b36-WASJ-6-6-00268"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><etal/></person-group><article-title>The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discov</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><year>2012</year><pub-id pub-id-type="pmid">22588877</pub-id><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id></element-citation></ref>
<ref id="b37-WASJ-6-6-00268"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>MCM2 in human cancer: Functions, mechanisms, and clinical significance</article-title><source>Mol Med</source><volume>28</volume><issue>128</issue><year>2022</year><pub-id pub-id-type="pmid">36303105</pub-id><pub-id pub-id-type="doi">10.1186/s10020-022-00555-9</pub-id></element-citation></ref>
<ref id="b38-WASJ-6-6-00268"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Statistical inference methods for two crossing survival curves: A comparison of methods</article-title><source>PLoS One</source><volume>10</volume><issue>e0116774</issue><year>2015</year><pub-id pub-id-type="pmid">25615624</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0116774</pub-id></element-citation></ref>
<ref id="b39-WASJ-6-6-00268"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Eyben</surname><given-names>FE</given-names></name><name><surname>Madsen</surname><given-names>EL</given-names></name><name><surname>Fritsche</surname><given-names>H</given-names></name><name><surname>Suciu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Amato</surname><given-names>R</given-names></name></person-group><article-title>A new prognostic model for testicular germ cell tumours</article-title><source>APMIS</source><volume>111</volume><fpage>100</fpage><lpage>105</lpage><year>2003</year><pub-id pub-id-type="pmid">12752246</pub-id><pub-id pub-id-type="doi">10.1034/j.1600-0463.2003.1110114_1.x</pub-id></element-citation></ref>
<ref id="b40-WASJ-6-6-00268"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghbash</surname><given-names>PS</given-names></name><name><surname>Hemmat</surname><given-names>N</given-names></name><name><surname>Fathi</surname><given-names>H</given-names></name><name><surname>Baghi</surname><given-names>HB</given-names></name></person-group><article-title>Monoclonal antibodies in cervical malignancy-related HPV</article-title><source>Front Oncol</source><volume>12</volume><issue>904790</issue><year>2022</year><pub-id pub-id-type="pmid">36276117</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2022.904790</pub-id></element-citation></ref>
<ref id="b41-WASJ-6-6-00268"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Psilopatis</surname><given-names>I</given-names></name><name><surname>Damaskos</surname><given-names>C</given-names></name><name><surname>Garmpi</surname><given-names>A</given-names></name><name><surname>Sarantis</surname><given-names>P</given-names></name><name><surname>Koustas</surname><given-names>E</given-names></name><name><surname>Antoniou</surname><given-names>EA</given-names></name><name><surname>Dimitroulis</surname><given-names>D</given-names></name><name><surname>Kouraklis</surname><given-names>G</given-names></name><name><surname>Karamouzis</surname><given-names>MV</given-names></name><name><surname>Vrettou</surname><given-names>K</given-names></name><etal/></person-group><article-title>FDA-approved monoclonal antibodies for unresectable hepatocellular carcinoma: What do we know so far?</article-title><source>Int J Mol Sci</source><volume>24</volume><issue>2685</issue><year>2023</year><pub-id pub-id-type="pmid">36769004</pub-id><pub-id pub-id-type="doi">10.3390/ijms24032685</pub-id></element-citation></ref>
<ref id="b42-WASJ-6-6-00268"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>CC</given-names></name><name><surname>Bai</surname><given-names>CX</given-names></name><name><surname>Guan</surname><given-names>ZZ</given-names></name><name><surname>Jiang</surname><given-names>GL</given-names></name><name><surname>Shi</surname><given-names>YK</given-names></name><name><surname>Wang</surname><given-names>MZ</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>YP</given-names></name><name><surname>Zhu</surname><given-names>YZ</given-names></name></person-group><article-title>Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: Data of subgroup analyses from MO19390 (SAiL) study</article-title><source>Clin Transl Oncol</source><volume>16</volume><fpage>463</fpage><lpage>468</lpage><year>2014</year><pub-id pub-id-type="pmid">24002945</pub-id><pub-id pub-id-type="doi">10.1007/s12094-013-1102-5</pub-id></element-citation></ref>
<ref id="b43-WASJ-6-6-00268"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><etal/></person-group><article-title>Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: A phase 3 randomized, double-blind study</article-title><source>EClinicalMedicine</source><volume>42</volume><issue>101187</issue><year>2021</year><pub-id pub-id-type="pmid">34841235</pub-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101187</pub-id></element-citation></ref>
<ref id="b44-WASJ-6-6-00268"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name></person-group><article-title>DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression</article-title><source>Sci Rep</source><volume>12</volume><issue>19775</issue><year>2022</year><pub-id pub-id-type="pmid">36396671</pub-id><pub-id pub-id-type="doi">10.1038/s41598-022-23837-y</pub-id></element-citation></ref>
<ref id="b45-WASJ-6-6-00268"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Ou</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Nong</surname><given-names>K</given-names></name><etal/></person-group><article-title>Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells</article-title><source>PLoS One</source><volume>8</volume><issue>e80789</issue><year>2013</year><pub-id pub-id-type="pmid">24324629</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0080789</pub-id></element-citation></ref>
<ref id="b46-WASJ-6-6-00268"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>High expression of DLGAP5 Indicates poor prognosis and immunotherapy in lung adenocarcinoma and promotes proliferation through regulation of the cell cycle</article-title><source>Dis Markers</source><volume>2023</volume><issue>9292536</issue><year>2023</year><pub-id pub-id-type="pmid">36712920</pub-id><pub-id pub-id-type="doi">10.1155/2023/9292536</pub-id></element-citation></ref>
<ref id="b47-WASJ-6-6-00268"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ju</surname><given-names>LL</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>YF</given-names></name><name><surname>Lu</surname><given-names>RJ</given-names></name><name><surname>Bian</surname><given-names>ZL</given-names></name><name><surname>Shao</surname><given-names>JG</given-names></name></person-group><article-title>Effect of NDC80 in human hepatocellular carcinoma</article-title><source>World J Gastroenterol</source><volume>23</volume><fpage>3675</fpage><lpage>3683</lpage><year>2017</year><pub-id pub-id-type="pmid">28611520</pub-id><pub-id pub-id-type="doi">10.3748/wjg.v23.i20.3675</pub-id></element-citation></ref>
<ref id="b48-WASJ-6-6-00268"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name></person-group><article-title>Upregulation of nuclear division cycle 80 contributes to therapeutic resistance via the promotion of autophagy-related protein-7-dependent autophagy in lung cancer</article-title><source>Front Pharmacol</source><volume>13</volume><issue>985601</issue><year>2022</year><pub-id pub-id-type="pmid">36105209</pub-id><pub-id pub-id-type="doi">10.3389/fphar.2022.985601</pub-id></element-citation></ref>
<ref id="b49-WASJ-6-6-00268"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group><article-title>Knockdown of DLGAP5 suppresses cell proliferation, induces G(2)/M phase arrest and apoptosis in ovarian cancer</article-title><source>Exp Ther Med</source><volume>22</volume><issue>1245</issue><year>2021</year><pub-id pub-id-type="pmid">34539841</pub-id><pub-id pub-id-type="doi">10.3892/etm.2021.10680</pub-id></element-citation></ref>
<ref id="b50-WASJ-6-6-00268"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CL</given-names></name><name><surname>He</surname><given-names>JT</given-names></name><name><surname>Li</surname><given-names>NN</given-names></name><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Ni</surname><given-names>HH</given-names></name><name><surname>Huang</surname><given-names>JT</given-names></name><name><surname>Liu</surname><given-names>GQ</given-names></name><name><surname>Wang</surname><given-names>JD</given-names></name><name><surname>Li</surname><given-names>YK</given-names></name><name><surname>Zhan</surname><given-names>GH</given-names></name><etal/></person-group><comment>Clinical value of PRC1 and DLGAP5 and immunosuppressive T cells overexpressing them in HCC based on transcriptome data. ResarchSquare. 2023. doi: 10.21203/rs.3.rs-2616803/v1.</comment></element-citation></ref>
<ref id="b51-WASJ-6-6-00268"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>Nuclear division cycle 80 complex is associated with malignancy and predicts poor survival of hepatocellular carcinoma</article-title><source>Int J Clin Exp Pathol</source><volume>12</volume><fpage>1233</fpage><lpage>1247</lpage><year>2019</year><pub-id pub-id-type="pmid">31933938</pub-id></element-citation></ref>
<ref id="b52-WASJ-6-6-00268"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name></person-group><article-title>ShRNA-mediated silencing of the Ndc80 gene suppress cell proliferation and affected hepatitis B virus-related hepatocellular carcinoma</article-title><source>Clin Res Hepatol Gastroenterol</source><volume>40</volume><fpage>297</fpage><lpage>303</lpage><year>2016</year><pub-id pub-id-type="pmid">26382282</pub-id><pub-id pub-id-type="doi">10.1016/j.clinre.2015.08.002</pub-id></element-citation></ref>
<ref id="b53-WASJ-6-6-00268"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>T</given-names></name><name><surname>Yi</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>LX</given-names></name><name><surname>Zhao</surname><given-names>JX</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>N</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>HO</given-names></name><name><surname>Li</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Identification of the DNA replication regulator MCM complex expression and prognostic significance in hepatic carcinoma</article-title><source>Biomed Res Int</source><volume>2020</volume><issue>3574261</issue><year>2020</year><pub-id pub-id-type="pmid">32964028</pub-id><pub-id pub-id-type="doi">10.1155/2020/3574261</pub-id></element-citation></ref>
<ref id="b54-WASJ-6-6-00268"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XK</given-names></name><name><surname>Wang</surname><given-names>QQ</given-names></name><name><surname>Huang</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>LB</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>JQ</given-names></name><name><surname>Chen</surname><given-names>ZJ</given-names></name><name><surname>Liao</surname><given-names>XW</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Novel candidate biomarkers of origin recognition complex 1, 5 and 6 for survival surveillance in patients with hepatocellular carcinoma</article-title><source>J Cancer</source><volume>11</volume><fpage>1869</fpage><lpage>1882</lpage><year>2020</year><pub-id pub-id-type="pmid">32194798</pub-id><pub-id pub-id-type="doi">10.7150/jca.39163</pub-id></element-citation></ref>
<ref id="b55-WASJ-6-6-00268"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Ru</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name></person-group><article-title>Prognostic implications of cell division cycle protein 45 expression in hepatocellular carcinoma</article-title><source>PeerJ</source><volume>9</volume><issue>e10824</issue><year>2021</year><pub-id pub-id-type="pmid">33614286</pub-id><pub-id pub-id-type="doi">10.7717/peerj.10824</pub-id></element-citation></ref>
<ref id="b56-WASJ-6-6-00268"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>F</given-names></name><name><surname>Shao</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>High expression of TOP2A gene predicted poor prognosis of hepatocellular carcinoma after radical hepatectomy</article-title><source>Transl Cancer Res</source><volume>9</volume><fpage>983</fpage><lpage>992</lpage><year>2020</year><pub-id pub-id-type="pmid">35117443</pub-id><pub-id pub-id-type="doi">10.21037/tcr.2019.12.46</pub-id></element-citation></ref>
<ref id="b57-WASJ-6-6-00268"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Moral-Hernandez</surname><given-names>O</given-names></name><name><surname>Hernandez-Sotelo</surname><given-names>D</given-names></name><name><surname>Alarcon-Romero</surname><given-names>LDC</given-names></name><name><surname>Mendoza-Catalan</surname><given-names>MA</given-names></name><name><surname>Flores-Alfaro</surname><given-names>E</given-names></name><name><surname>Castro-Coronel</surname><given-names>Y</given-names></name><name><surname>Ortiz-Ortiz</surname><given-names>J</given-names></name><name><surname>Leyva-Vázquez</surname><given-names>MA</given-names></name><name><surname>Ortuño-Pineda</surname><given-names>C</given-names></name><name><surname>Castro-Mora</surname><given-names>W</given-names></name><name><surname>Illades-Aguiar</surname><given-names>B</given-names></name></person-group><article-title>TOP2A/MCM2, p16(INK4a), and cyclin E1 expression in liquid-based cytology: A biomarkers panel for progression risk of cervical premalignant lesions</article-title><source>BMC Cancer</source><volume>21</volume><issue>39</issue><year>2021</year><pub-id pub-id-type="pmid">33413211</pub-id><pub-id pub-id-type="doi">10.1186/s12885-020-07740-1</pub-id></element-citation></ref>
<ref id="b58-WASJ-6-6-00268"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wan</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Expression and prognosis of CDC45 in cervical cancer based on the GEO database</article-title><source>PeerJ</source><volume>9</volume><issue>e12114</issue><year>2021</year><pub-id pub-id-type="pmid">34557356</pub-id><pub-id pub-id-type="doi">10.7717/peerj.12114</pub-id></element-citation></ref>
<ref id="b59-WASJ-6-6-00268"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Mei</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>Up-regulated lncRNA XIST contributes to progression of cervical cancer via regulating miR-140-5p and ORC1</article-title><source>Cancer Cell Int</source><volume>19</volume><issue>45</issue><year>2019</year><pub-id pub-id-type="pmid">30858762</pub-id><pub-id pub-id-type="doi">10.1186/s12935-019-0744-y</pub-id></element-citation></ref>
<ref id="b60-WASJ-6-6-00268"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Qu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Bioinformatics analysis reveals MCM3 as an important prognostic marker in cervical cancer</article-title><source>Comput Math Methods Med</source><volume>2021</volume><issue>8494260</issue><year>2021</year><pub-id pub-id-type="pmid">34671420</pub-id><pub-id pub-id-type="doi">10.1155/2021/8494260</pub-id></element-citation></ref>
<ref id="b61-WASJ-6-6-00268"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Lan</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>S</given-names></name></person-group><article-title>Multi-Omics analysis of MCM2 as a promising biomarker in pan-cancer</article-title><source>Front Cell Dev Biol</source><volume>10</volume><issue>852135</issue><year>2022</year><pub-id pub-id-type="pmid">35693940</pub-id><pub-id pub-id-type="doi">10.3389/fcell.2022.852135</pub-id></element-citation></ref>
<ref id="b62-WASJ-6-6-00268"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name></person-group><article-title>Origin recognition complex subunit 1(ORC1) is a potential biomarker and therapeutic target in cancer</article-title><source>BMC Med Genomics</source><volume>16</volume><issue>243</issue><year>2023</year><pub-id pub-id-type="pmid">37833711</pub-id><pub-id pub-id-type="doi">10.1186/s12920-023-01691-9</pub-id></element-citation></ref>
<ref id="b63-WASJ-6-6-00268"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p</article-title><source>J Cancer</source><volume>13</volume><fpage>589</fpage><lpage>601</lpage><year>2022</year><pub-id pub-id-type="pmid">35069905</pub-id><pub-id pub-id-type="doi">10.7150/jca.64017</pub-id></element-citation></ref>
<ref id="b64-WASJ-6-6-00268"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyritsis</surname><given-names>KA</given-names></name><name><surname>Akrivou</surname><given-names>MG</given-names></name><name><surname>Giassafaki</surname><given-names>LP</given-names></name><name><surname>Grigoriadis</surname><given-names>NG</given-names></name><name><surname>Vizirianakis</surname><given-names>IS</given-names></name></person-group><article-title>Analysis of TCGA data of differentially expressed EMT-related genes and miRNAs across various malignancies to identify potential biomarkers</article-title><source>World Academy Of Sciences Journal</source><volume>3</volume><issue>6</issue><year>2021</year></element-citation></ref>
<ref id="b65-WASJ-6-6-00268"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>J</given-names></name><name><surname>Mariot</surname><given-names>C</given-names></name><name><surname>Vianna</surname><given-names>DRB</given-names></name><name><surname>Kliemann</surname><given-names>LM</given-names></name><name><surname>Chaves</surname><given-names>PS</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Buffon</surname><given-names>A</given-names></name><name><surname>Beck</surname><given-names>RCR</given-names></name><name><surname>Pilger</surname><given-names>DA</given-names></name></person-group><article-title>Fatty acid synthase as a potential new therapeutic target for cervical cancer</article-title><source>An Acad Bras Cienc</source><volume>94</volume><issue>e20210670</issue><year>2022</year><pub-id pub-id-type="pmid">35507982</pub-id><pub-id pub-id-type="doi">10.1590/0001-3765202220210670</pub-id></element-citation></ref>
<ref id="b66-WASJ-6-6-00268"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myung</surname><given-names>SJ</given-names></name><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Yu</surname><given-names>SJ</given-names></name></person-group><article-title>STAT3 &amp; Cytochrome P450 2C9: A novel signaling pathway in liver cancer stem cells</article-title><source>Biomed Pharmacother</source><volume>66</volume><fpage>612</fpage><lpage>616</lpage><year>2012</year><pub-id pub-id-type="pmid">23089473</pub-id><pub-id pub-id-type="doi">10.1016/j.biopha.2012.08.011</pub-id></element-citation></ref>
<ref id="b67-WASJ-6-6-00268"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><etal/></person-group><article-title>ACADS acts as a potential methylation biomarker associated with the proliferation and metastasis of hepatocellular carcinomas</article-title><source>Aging (Albany NY)</source><volume>11</volume><fpage>8825</fpage><lpage>8844</lpage><year>2019</year><pub-id pub-id-type="pmid">31652420</pub-id><pub-id pub-id-type="doi">10.18632/aging.102292</pub-id></element-citation></ref>
<ref id="b68-WASJ-6-6-00268"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liersch</surname><given-names>T</given-names></name><name><surname>Langer</surname><given-names>C</given-names></name><name><surname>Ghadimi</surname><given-names>BM</given-names></name><name><surname>Kulle</surname><given-names>B</given-names></name><name><surname>Aust</surname><given-names>DE</given-names></name><name><surname>Baretton</surname><given-names>GB</given-names></name><name><surname>Schwabe</surname><given-names>W</given-names></name><name><surname>Häusler</surname><given-names>P</given-names></name><name><surname>Becker</surname><given-names>H</given-names></name><name><surname>Jakob</surname><given-names>C</given-names></name></person-group><article-title>Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy</article-title><source>J Clin Oncol</source><volume>24</volume><fpage>4062</fpage><lpage>4068</lpage><year>2006</year><pub-id pub-id-type="pmid">16943523</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.04.2739</pub-id></element-citation></ref>
<ref id="b69-WASJ-6-6-00268"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>TH</given-names></name><name><surname>Chiu</surname><given-names>JY</given-names></name><name><surname>Shih</surname><given-names>KH</given-names></name></person-group><article-title>A 23-gene prognostic classifier for prediction of recurrence and survival for Asian breast cancer patients</article-title><source>Biosci Rep</source><volume>40</volume><issue>BSR20202794</issue><year>2020</year><pub-id pub-id-type="pmid">33226082</pub-id><pub-id pub-id-type="doi">10.1042/BSR20202794</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-WASJ-6-6-00268" position="float">
<label>Figure 1</label>
<caption><p>Network analysis of the common genes present in, lung, cervical and liver cancer.</p></caption>
<graphic xlink:href="wasj-06-06-00268-g00.tif"/>
</fig>
<fig id="f2-WASJ-6-6-00268" position="float">
<label>Figure 2</label>
<caption><p>Heatmap analysis of top 70 common hub genes present in (A) lung, (B) cervical, and (C) liver cancer. TS, tumor sample; NS, normal sample.</p></caption>
<graphic xlink:href="wasj-06-06-00268-g01.tif"/>
</fig>
<fig id="f3-WASJ-6-6-00268" position="float">
<label>Figure 3</label>
<caption><p>Overall survival analysis of patients with a low or high expression of the <italic>DLGAP5</italic> and <italic>NDC80</italic> genes in (A) liver and (B) lung cancer. <italic>DLGAP5, human disks large-associated protein 5; NDC80, human NDC80 kinetochore complex component</italic>.</p></caption>
<graphic xlink:href="wasj-06-06-00268-g02.tif"/>
</fig>
<fig id="f4-WASJ-6-6-00268" position="float">
<label>Figure 4</label>
<caption><p>Overall survival analysis of patients with a low or high expression of the <italic>MCM2</italic>, <italic>MCM3</italic>, <italic>ORC1</italic>, <italic>CDC45</italic> and <italic>TOP2A</italic> genes in (A) liver and (B) cervical cancer. <italic>MCM, human minichromosome maintenance complex component; ORC1, origin recognition complex subunit 1; CDC45, cell division cycle 45; TOP2A, human DNA topoisomerase II alpha</italic>.</p></caption>
<graphic xlink:href="wasj-06-06-00268-g03.tif"/>
</fig>
<fig id="f5-WASJ-6-6-00268" position="float">
<label>Figure 5</label>
<caption><p>DFS of patients with a low or high expression of the <italic>DLGAP5</italic> and <italic>NDC80</italic> genes in (A) liver, and (B) lung cancer. DFS, disease-free survival; <italic>DLGAP5, human disks large-associated protein 5; NDC80, human NDC80 kinetochore complex component</italic>.</p></caption>
<graphic xlink:href="wasj-06-06-00268-g04.tif"/>
</fig>
<fig id="f6-WASJ-6-6-00268" position="float">
<label>Figure 6</label>
<caption><p>DFS analysis of patients with a low or high expression of the <italic>MCM2</italic>, <italic>MCM3</italic>, <italic>ORC1</italic>, <italic>CDC45</italic> and <italic>TOP2A</italic> genes in (A) liver, and (B) cervical cancer. DFS, disease-free survival; <italic>MCM, human minichromosome maintenance complex component; ORC1, origin recognition complex subunit 1; CDC45, cell division cycle 45; TOP2A, human DNA topoisomerase II alpha.</italic></p></caption>
<graphic xlink:href="wasj-06-06-00268-g05.tif"/>
</fig>
<fig id="f7-WASJ-6-6-00268" position="float">
<label>Figure 7</label>
<caption><p>Reverse transcription-quantitative PCR analysis of (A) <italic>DLGAP5</italic>, (B) <italic>MCM3</italic>, (C) <italic>NDC80</italic>, and (D) <italic>TOP2A</italic> genes in patients with oral cancer. NS, not significant; <italic>DLGAP5, human disks large-associated protein 5; NDC80, human NDC80 kinetochore complex component; MCM3, human minichromosome maintenance complex component 3; TOP2A, human DNA topoisomerase II alpha.</italic></p></caption>
<graphic xlink:href="wasj-06-06-00268-g06.tif"/>
</fig>
<fig id="f8-WASJ-6-6-00268" position="float">
<label>Figure 8</label>
<caption><p>Molecular dynamics simulation study of <italic>NDC80</italic> and cytochalasin B complex. (A) Root mean square deviation, (B) root mean square fluctuations, and (C) radius of gyration for the time duration of 50 nsec. RMSD, toot mean square deviation; RMSF, root mean square fluctuations.</p></caption>
<graphic xlink:href="wasj-06-06-00268-g07.tif"/>
</fig>
<table-wrap id="tI-WASJ-6-6-00268" position="float">
<label>Table I</label>
<caption><p>Common hub genes significantly affecting the survival of patients with lung, cervical and liver cancer</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Lung</th>
<th align="center" valign="middle">Cervical</th>
<th align="center" valign="middle">Liver</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">DLGAP5, NDC80, POLE2, CASC5, CHEK1, WDHD1</td>
<td align="left" valign="middle">MCM2, ORC1, CDC45, MCM3, TOP2A, PCNA, RFC4, RRM2, EXO1</td>
<td align="left" valign="middle">CDK1, CCNA2, CDC20, BUB1B, CCNB1, BUB1, KIF11, PLK1, KIF20A, DLGAP5, TOP2A, DBF4, MCM3, RAD51, MCM10, ASPM, HMMR, MCM2, MCM6, SPAG5, NDC80, ORC1, AURKA, TPX2, BIRC5, KIF4A, CLSPN, CDC45, CDC6, CDC7, MCM5, MCM4, NCAPG, FOXM1, CDCA3, TKK, CENPA, NEK2, CENPF, KIF14, CCNA2</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="tII-WASJ-6-6-00268" position="float">
<label>Table II</label>
<caption><p>Survival analysis of the common DEGs identified in lung and liver cancer from the cBioPortal database.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">SN</th>
<th align="center" valign="middle">Gene symbol</th>
<th align="center" valign="middle">Cancer type</th>
<th align="center" valign="middle">Risk of disease (no. of patients)</th>
<th align="center" valign="middle">Survival/deceased status (no. of patients)</th>
<th align="center" valign="middle">P-value (OS)</th>
<th align="center" valign="middle">Disease free survival/recurred status (no. of patients)</th>
<th align="center" valign="middle">P-value (DFS)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">1</td>
<td align="left" valign="middle">NDC80</td>
<td align="left" valign="middle">Lung</td>
<td align="left" valign="middle">High risk (32)</td>
<td align="left" valign="middle">OS (23)</td>
<td align="left" valign="middle">0.09</td>
<td align="left" valign="middle">DFS (21)</td>
<td align="left" valign="middle">0.100348</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">(CO=0.070±0.001)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (9)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (11)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (40)</td>
<td align="left" valign="middle">OS (35)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (33)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (5)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (7)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">2</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Liver</td>
<td align="left" valign="middle">High risk (131)</td>
<td align="left" valign="middle">OS (91)</td>
<td align="left" valign="middle">0.036<sup><xref rid="tfna-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (48)</td>
<td align="left" valign="middle">0.002974<sup><xref rid="tfna-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">(CO=11.26±0.78)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (40)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (83)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (143)</td>
<td align="left" valign="middle">OS (115)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (78)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (28)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (65)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">3</td>
<td align="left" valign="middle">DLGAP5</td>
<td align="left" valign="middle">Liver</td>
<td align="left" valign="middle">High risk (134)</td>
<td align="left" valign="middle">OS (89)</td>
<td align="left" valign="middle">0.004378<sup><xref rid="tfna-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (49)</td>
<td align="left" valign="middle">0.675183</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">(CO=9.01±0.79).</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (45)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (40)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (136)</td>
<td align="left" valign="middle">OS (111)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (71)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (25)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (65)</td>
<td align="left" valign="middle"> </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>The numbers in parentheses indicate the number of patients.</p></fn>
<fn id="tfna-WASJ-6-6-00268"><p><sup>a</sup>Indicates a statistically significant difference (P≤0.05). DEGs, differentially expressed genes; OS, overall survival; DFS, disease-free survival; CO, cut-off value; <italic>DLGAP5</italic>, human disks large-associated protein 5; <italic>NDC80</italic>, human NDC80 kinetochore complex component.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIII-WASJ-6-6-00268" position="float">
<label>Table III</label>
<caption><p>Survival analysis of the common DEGs identified in cervical and liver cancer from cBioPortal database.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">SN</th>
<th align="center" valign="middle">Gene symbol</th>
<th align="center" valign="middle">Cancer type</th>
<th align="center" valign="middle">Expression</th>
<th align="center" valign="middle">Details</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">Details</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">1</td>
<td align="left" valign="middle">MCM2</td>
<td align="left" valign="middle">Cervical</td>
<td align="left" valign="middle">High risk (103)</td>
<td align="left" valign="middle">OS (88)</td>
<td align="left" valign="middle">0.48812</td>
<td align="left" valign="middle">DFS (84)</td>
<td align="left" valign="middle">0.996133</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=137.56±3.94</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (15)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (19)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (114)</td>
<td align="left" valign="middle">OS (101)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (93)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (13)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (21)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">2</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Liver</td>
<td align="left" valign="middle">High risk (132)</td>
<td align="left" valign="middle">OS (89)</td>
<td align="left" valign="middle">0.015686<sup><xref rid="tfn1-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (49)</td>
<td align="left" valign="middle">0.506711</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=44.62±3.54</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (43)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (39)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (133)</td>
<td align="left" valign="middle">OS (107)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (68)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (26)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (65)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">3</td>
<td align="left" valign="middle">MCM3</td>
<td align="left" valign="middle">Cervical</td>
<td align="left" valign="middle">High risk (106)</td>
<td align="left" valign="middle">OS (94)</td>
<td align="left" valign="middle">0.953041</td>
<td align="left" valign="middle">DFS (89)</td>
<td align="left" valign="middle">0.3708</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=99.87±1.98</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (12)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (17)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (121)</td>
<td align="left" valign="middle">OS (107)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (96)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (14)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (25)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">4</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Liver</td>
<td align="left" valign="middle">High risk (134)</td>
<td align="left" valign="middle">OS (94)</td>
<td align="left" valign="middle">0.033606<sup><xref rid="tfn1-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (52)</td>
<td align="left" valign="middle">0.011974<sup><xref rid="tfn1-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=68.32±3.07</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (40)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (82)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (129)</td>
<td align="left" valign="middle">OS (105)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (70)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (26)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (59)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">5</td>
<td align="left" valign="middle">ORC1</td>
<td align="left" valign="middle">Cervical</td>
<td align="left" valign="middle">High risk (109)</td>
<td align="left" valign="middle">OS (93)</td>
<td align="left" valign="middle">0.564918</td>
<td align="left" valign="middle">DFS (85)</td>
<td align="left" valign="middle">0.211026</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=11.22±0.25</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (16)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (24)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (116)</td>
<td align="left" valign="middle">OS (102)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS-98</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (14)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred-18</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">6</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Liver</td>
<td align="left" valign="middle">High risk (121)</td>
<td align="left" valign="middle">OS (85)</td>
<td align="left" valign="middle">0.01449<sup><xref rid="tfn1-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (45)</td>
<td align="left" valign="middle">0.018018<sup><xref rid="tfn1-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=5.50±0.47</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (36)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (76)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (141)</td>
<td align="left" valign="middle">OS (117)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (73)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (24)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (68)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">7</td>
<td align="left" valign="middle">CDC45</td>
<td align="left" valign="middle">Cervical</td>
<td align="left" valign="middle">High risk (101)</td>
<td align="left" valign="middle">OS (89)</td>
<td align="left" valign="middle">0.931737</td>
<td align="left" valign="middle">DFS (79)</td>
<td align="left" valign="middle">0.272893</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=18.92±0.54</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (12)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (22)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (113)</td>
<td align="left" valign="middle">OS (100)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (95)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (13)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (79)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">8</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Liver</td>
<td align="left" valign="middle">High risk (137)</td>
<td align="left" valign="middle">OS (94)</td>
<td align="left" valign="middle">0.005112<sup><xref rid="tfn1-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (52)</td>
<td align="left" valign="middle">0.007663<sup><xref rid="tfn1-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=8.11±0.64</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (43)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (85)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (141)</td>
<td align="left" valign="middle">OS (117)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (76)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (24)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (65)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">9</td>
<td align="left" valign="middle">TOP2A</td>
<td align="left" valign="middle">Cervical</td>
<td align="left" valign="middle">High risk (104)</td>
<td align="left" valign="middle">OS (91)</td>
<td align="left" valign="middle">0.784725</td>
<td align="left" valign="middle">DFS (87)</td>
<td align="left" valign="middle">0.708667</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=130.7±3.68</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (13)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (17)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (115)</td>
<td align="left" valign="middle">OS (102)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (94)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (13)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (21)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">10</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Liver</td>
<td align="left" valign="middle">High (141)</td>
<td align="left" valign="middle">OS (99)</td>
<td align="left" valign="middle">0.098857</td>
<td align="left" valign="middle">DFS (54)</td>
<td align="left" valign="middle">0.015001<sup><xref rid="tfn1-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">CO=68.27±6.49</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (42)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (87)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low (120)</td>
<td align="left" valign="middle">OS-95</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (64)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (25)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (56)</td>
<td align="left" valign="middle"> </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>The numbers in parentheses indicate the number of patients.</p></fn>
<fn id="tfn1-a-WASJ-6-6-00268"><p><sup>a</sup>Indicates a statistically significant difference (P≤0.05). DEGs, differentially expressed genes; OS, overall survival; DFS, disease-free survival; CO, cut-off value; <italic>MCM</italic>, human minichromosome maintenance complex component; <italic>ORC1</italic>, origin recognition complex subunit 1; <italic>CDC45</italic>, cell division cycle 45; <italic>TOP2A</italic>, human DNA topoisomerase II alpha.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIV-WASJ-6-6-00268" position="float">
<label>Table IV</label>
<caption><p>Unique genes significantly impacting the survival of lung, cervical and liver cancer.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Lung</th>
<th align="center" valign="middle">Cervical</th>
<th align="center" valign="middle">Liver</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">ALDOC, FN1, SNPRG</td>
<td align="left" valign="middle">CSF2, SCD, DNAJC9, FANCM, USP18, FASN, RUNX1, NASP</td>
<td align="left" valign="middle">RPL38, RPS21, CYP2C9, RPL8, CYP2C8, NDUFS3, MT-CO1, MT-CYB, ABAT, ACADS, AKR1D1, AGXT2, ACAA1, SHARPIN, RPSA, RBCK1, RIPK2, RPS5, TRAF5, APOC3, ECHS1, SARDH, HSD17B8</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="tV-WASJ-6-6-00268" position="float">
<label>Table V</label>
<caption><p>Survival analysis of the unique DEGs identified in lung, cervical and liver cancer from the cBioPortal database.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">SN</th>
<th align="center" valign="middle">Cancer type</th>
<th align="center" valign="middle">Total no. of patients</th>
<th align="center" valign="middle">Gene symbol</th>
<th align="center" valign="middle">Risk status (no. of patients)</th>
<th align="center" valign="middle">Survival/deceased status (no. of patients)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">Disease free survival/recurrence status (no. of patients)</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">1</td>
<td align="left" valign="middle">Lung</td>
<td align="center" valign="middle">133</td>
<td align="left" valign="middle">ALDOC</td>
<td align="left" valign="middle">High risk (37)</td>
<td align="left" valign="middle">OS-(29)</td>
<td align="left" valign="middle">0.860901</td>
<td align="left" valign="middle">DFS (27)</td>
<td align="left" valign="middle">0.839395</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (8)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (10)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (40)</td>
<td align="left" valign="middle">OS-(32)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (30)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (8)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (10)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">2</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">SNRPG</td>
<td align="left" valign="middle">High risk (43)</td>
<td align="left" valign="middle">OS (34)</td>
<td align="left" valign="middle">0.617942</td>
<td align="left" valign="middle">DFS (32)</td>
<td align="left" valign="middle">0.858053</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (9)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (11)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (35)</td>
<td align="left" valign="middle">OS (26)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (32)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (9)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (12)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">3</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">FN1</td>
<td align="left" valign="middle">High risk (9)</td>
<td align="left" valign="middle">OS (6)</td>
<td align="left" valign="middle">0.701063</td>
<td align="left" valign="middle">DFS (6)</td>
<td align="left" valign="middle">0.856395</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (3)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (3)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (19)</td>
<td align="left" valign="middle">OS (14)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (12)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (5)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (7)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">4</td>
<td align="left" valign="middle">Cervical</td>
<td align="center" valign="middle">304</td>
<td align="left" valign="middle">FANCM</td>
<td align="left" valign="middle">High risk (108)</td>
<td align="left" valign="middle">OS (98)</td>
<td align="left" valign="middle">0.003825</td>
<td align="left" valign="middle">DFS (91)</td>
<td align="left" valign="middle">0.923519</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (10)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (17)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (111)</td>
<td align="left" valign="middle">OS (98)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (93)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (30)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (18)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">5</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">USP18</td>
<td align="left" valign="middle">High risk (104)</td>
<td align="left" valign="middle">OS (89)</td>
<td align="left" valign="middle">0.521714</td>
<td align="left" valign="middle">DFS (82)</td>
<td align="left" valign="middle">0.414601</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (15)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (22)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (113)</td>
<td align="left" valign="middle">OS (100)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (94)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (13)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (19)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">6</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">DNAJC9</td>
<td align="left" valign="middle">High risk (109)</td>
<td align="left" valign="middle">OS (93)</td>
<td align="left" valign="middle">0.582174</td>
<td align="left" valign="middle">DFS (83)</td>
<td align="left" valign="middle">0.171057</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (16)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (26)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (115)</td>
<td align="left" valign="middle">OS (101)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (96)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (14)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (19)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">7</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">FASN</td>
<td align="left" valign="middle">High risk (103)</td>
<td align="left" valign="middle">OS (85)</td>
<td align="left" valign="middle">0.016737<sup><xref rid="tfn2-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (77)</td>
<td align="left" valign="middle">0.007345<sup><xref rid="tfn2-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (18)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (26)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (115)</td>
<td align="left" valign="middle">OS (107)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (102)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (8)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (13)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">8</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">RUNX1</td>
<td align="left" valign="middle">High risk (113)</td>
<td align="left" valign="middle">OS (97)</td>
<td align="left" valign="middle">0.179014</td>
<td align="left" valign="middle">DFS (86)</td>
<td align="left" valign="middle">0.029777</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (16)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (27)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (117)</td>
<td align="left" valign="middle">OS (107)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (102)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (10)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (15)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">9</td>
<td align="left" valign="middle">Liver</td>
<td align="center" valign="middle">371</td>
<td align="left" valign="middle">RPL38</td>
<td align="left" valign="middle">High risk (127)</td>
<td align="left" valign="middle">OS (92)</td>
<td align="left" valign="middle">0.635329</td>
<td align="left" valign="middle">DFS (53)</td>
<td align="left" valign="middle">0.519766</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (35)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (74)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (100)</td>
<td align="left" valign="middle">OS (73)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (46)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (24)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (54)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">10</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">RPS21</td>
<td align="left" valign="middle">High risk (119)</td>
<td align="left" valign="middle">OS (84)</td>
<td align="left" valign="middle">0.226981</td>
<td align="left" valign="middle">DFS (47)</td>
<td align="left" valign="middle">0.247757</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (35)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (72)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk -(95)</td>
<td align="left" valign="middle">OS (74)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (45)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (21)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (50)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">11</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">RPL8</td>
<td align="left" valign="middle">High risk (117)</td>
<td align="left" valign="middle">OS (90)</td>
<td align="left" valign="middle">0.989298</td>
<td align="left" valign="middle">DFS (54)</td>
<td align="left" valign="middle">0.864929</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (27)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (63)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (100)</td>
<td align="left" valign="middle">OS (77)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (45)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (23)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (55)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">12</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">CYP2C9</td>
<td align="left" valign="middle">High risk 116)</td>
<td align="left" valign="middle">OS (78)</td>
<td align="left" valign="middle">0.013493<sup><xref rid="tfn2-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (41)</td>
<td align="left" valign="middle">0.025993<sup><xref rid="tfn2-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (38)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (75)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (149)</td>
<td align="left" valign="middle">OS (120)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (73)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (29)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (76)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">13</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">CYP2C8</td>
<td align="left" valign="middle">High risk (130)</td>
<td align="left" valign="middle">OS (92)</td>
<td align="left" valign="middle">0.133773</td>
<td align="left" valign="middle">DFS (51)</td>
<td align="left" valign="middle">0.104747</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (38)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (79)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (145)</td>
<td align="left" valign="middle">OS (114)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (71)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (31)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (74)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">14</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">NDUFS3</td>
<td align="left" valign="middle">High risk (136)</td>
<td align="left" valign="middle">OS (101)</td>
<td align="left" valign="middle">0.672898</td>
<td align="left" valign="middle">DFS (60)</td>
<td align="left" valign="middle">0.90272</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (35)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (76)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (136)</td>
<td align="left" valign="middle">OS (104)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (59)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (32)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (77)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">15</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">ABAT</td>
<td align="left" valign="middle">High risk (125)</td>
<td align="left" valign="middle">OS (85)</td>
<td align="left" valign="middle">0.038715</td>
<td align="left" valign="middle">DFS (47)</td>
<td align="left" valign="middle">0.050122</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (40)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (78)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (152)</td>
<td align="left" valign="middle">OS (120)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (75)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (32)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (77)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">16</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">ACADS</td>
<td align="left" valign="middle">High risk (127)</td>
<td align="left" valign="middle">OS (85)</td>
<td align="left" valign="middle">0.014895<sup><xref rid="tfn2-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
<td align="left" valign="middle">DFS (49)</td>
<td align="left" valign="middle">0.007165<sup><xref rid="tfn2-a-WASJ-6-6-00268" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (42)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (78)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (136)</td>
<td align="left" valign="middle">OS (109)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (75)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (27)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (61)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">17</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">AKR1D1</td>
<td align="left" valign="middle">High risk (95)</td>
<td align="left" valign="middle">OS (66)</td>
<td align="left" valign="middle">0.125758</td>
<td align="left" valign="middle">DFS (36)</td>
<td align="left" valign="middle">0.071368</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (29)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (59)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (131)</td>
<td align="left" valign="middle">OS (102)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (65)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (28)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (65)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">18</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">AGXT2</td>
<td align="left" valign="middle">High risk (131)</td>
<td align="left" valign="middle">OS (95)</td>
<td align="left" valign="middle">0.187204</td>
<td align="left" valign="middle">DFS (55)</td>
<td align="left" valign="middle">0.188999</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (36)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (76)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (136)</td>
<td align="left" valign="middle">OS (108)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (68)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (28)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (68)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">19</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">ACAA1</td>
<td align="left" valign="middle">High risk (139)</td>
<td align="left" valign="middle">OS (99)</td>
<td align="left" valign="middle">0.121543</td>
<td align="left" valign="middle">DFS (53)</td>
<td align="left" valign="middle">0.024599</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (40)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (86)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk-(144)</td>
<td align="left" valign="middle">OS (114)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (77)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (30)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (76)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">20</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">SHARPIN</td>
<td align="left" valign="middle">High risk -(132)</td>
<td align="left" valign="middle">OS (103)</td>
<td align="left" valign="middle">0.777398</td>
<td align="left" valign="middle">DFS (61)</td>
<td align="left" valign="middle">0.786172</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (28)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (70)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk -(132)</td>
<td align="left" valign="middle">OS (98)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (57)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (29)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (70)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">21</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">RPSA</td>
<td align="left" valign="middle">High risk (122)</td>
<td align="left" valign="middle">OS (86)</td>
<td align="left" valign="middle">0.165274</td>
<td align="left" valign="middle">DFS (49)</td>
<td align="left" valign="middle">0.218615</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (37)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (74)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (113)</td>
<td align="left" valign="middle">OS (88)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (54)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased-(25)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (59)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">22</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">RBCK1</td>
<td align="left" valign="middle">High risk (128)</td>
<td align="left" valign="middle">OS (94)</td>
<td align="left" valign="middle">0.801019</td>
<td align="left" valign="middle">DFS (65)</td>
<td align="left" valign="middle">0.354948</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (34)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (63)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (131)</td>
<td align="left" valign="middle">OS (98)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (59)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (33)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (72)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">23</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">RIPK2</td>
<td align="left" valign="middle">High risk (127)</td>
<td align="left" valign="middle">OS (91)</td>
<td align="left" valign="middle">0.265504</td>
<td align="left" valign="middle">DFS (53)</td>
<td align="left" valign="middle">0.08948</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (36)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (74)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (130)</td>
<td align="left" valign="middle">OS (101)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (68)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (29)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (62)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">24</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">RPS5</td>
<td align="left" valign="middle">High risk (114)</td>
<td align="left" valign="middle">OS (78)</td>
<td align="left" valign="middle">0.136647</td>
<td align="left" valign="middle">DFS (45)</td>
<td align="left" valign="middle">0.348421</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (36)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (69)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (114)</td>
<td align="left" valign="middle">OS (88)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (52)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (26)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (62)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">25</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">TRAF5</td>
<td align="left" valign="middle">High risk (139)</td>
<td align="left" valign="middle">OS (100)</td>
<td align="left" valign="middle">0.36903</td>
<td align="left" valign="middle">DFS (55)</td>
<td align="left" valign="middle">0.161267</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (39)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (84)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (129)</td>
<td align="left" valign="middle">OS (99)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (62)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (30)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (67)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">26</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">APOC3</td>
<td align="left" valign="middle">High risk (121)</td>
<td align="left" valign="middle">OS (87)</td>
<td align="left" valign="middle">0.215545</td>
<td align="left" valign="middle">DFS (49)</td>
<td align="left" valign="middle">0.07654</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (34)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (72)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (144)</td>
<td align="left" valign="middle">OS (113)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (74)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (31)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (70)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">27</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">ECHS1</td>
<td align="left" valign="middle">High risk (128)</td>
<td align="left" valign="middle">OS (97)</td>
<td align="left" valign="middle">0.630766</td>
<td align="left" valign="middle">DFS (54)</td>
<td align="left" valign="middle">0.20164</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (31)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (74)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (138)</td>
<td align="left" valign="middle">OS (108)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (69)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (30)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (69)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">28</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">SARDH</td>
<td align="left" valign="middle">High risk (133)</td>
<td align="left" valign="middle">OS (92)</td>
<td align="left" valign="middle">0.071347</td>
<td align="left" valign="middle">DFS (52)</td>
<td align="left" valign="middle">0.046716</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (41)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (81)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (128)</td>
<td align="left" valign="middle">OS (111)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (72)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (30)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (69)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle">29</td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle">HSD17B8</td>
<td align="left" valign="middle">High risk (127)</td>
<td align="left" valign="middle">OS (91)</td>
<td align="left" valign="middle">0.436891</td>
<td align="left" valign="middle">DFS (48)</td>
<td align="left" valign="middle">0.06633</td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (36)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (79)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Low risk (107)</td>
<td align="left" valign="middle">OS (107)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">DFS (69)</td>
<td align="left" valign="middle"> </td>
</tr>
<tr>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="center" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Deceased (34)</td>
<td align="left" valign="middle"> </td>
<td align="left" valign="middle">Recurred (72)</td>
<td align="left" valign="middle"> </td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>The numbers in parentheses indicate the number of patients.</p></fn>
<fn id="tfn2-a-WASJ-6-6-00268"><p><sup>a</sup>Indicates a statistically significant difference (P≤0.05). DEGs, differentially expressed genes; OS, overall survival; DFS, disease-free survival; CO, cut-off value.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
